# EDGAR Filing Document

**Accession Number:** 0001814287
**File Stem:** 0001628280-26-033136
**Filing Date:** 2026-5
**Character Count:** 199148
**Document Hash:** 9ebf84b20f459566309f274afe2b70cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-033136.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001628280-26-033136

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 123

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Abacus Global Management, Inc.
- **CENTRAL INDEX KEY:** 0001814287
- **STANDARD INDUSTRIAL CLASSIFICATION:** INVESTMENT ADVICE [6282]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 851210472
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39403
- **FILM NUMBER:** 26960898

**BUSINESS ADDRESS:**
- **STREET 1:** 2101 PARK CENTER DRIVE, SUITE 200
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32835
- **BUSINESS PHONE:** (800) 561-4148

**MAIL ADDRESS:**
- **STREET 1:** 2101 PARK CENTER DRIVE, SUITE 200
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32835

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Abacus Life, Inc.
- **DATE OF NAME CHANGE:** 20230705

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** East Resources Acquisition Co
- **DATE OF NAME CHANGE:** 20200605

?xml version='1.0' encoding='ASCII'? abx-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q** 

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _____ to _____**

**Commission file number 001-39403**![ABACUS GLOBAL_V_COLOR.jpg](abx-20260331_g1.jpg)

**Abacus Global Management, Inc.** 

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **85-1210472** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **2101 Park Center Drive, Suite 200**<br>**Orlando Florida** | **32835** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**(800) 561-4148** 

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share | ABX | New York Stock Exchange |
| 9.875% Fixed Rate Senior Notes due 2028 | ABXL | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer  | □ | Smaller reporting company | ⌧ |
| | | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;□

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;&nbsp;&nbsp;&nbsp;Yes □&nbsp;&nbsp;&nbsp;&nbsp; No ⌧

The registrant had 95,922,367 shares of common stock, $0.0001 par value per share, issued and outstanding as of May 1, 2026.

**ABACUS GLOBAL MANAGEMENT, INC.**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| | <u>[PART I. FINANCIAL INFORMATION](#i8f8164e49047434386656455d13714da_10)</u> | |
| <u>[Item 1.](#i8f8164e49047434386656455d13714da_760)</u> | <u>[Financial Statements (Unaudited)](#i8f8164e49047434386656455d13714da_760)</u> |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Balance Sheets](#i8f8164e49047434386656455d13714da_61)</u> | [1](#i8f8164e49047434386656455d13714da_61) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Operations and Comprehensive Income](#i8f8164e49047434386656455d13714da_64)</u> | [3](#i8f8164e49047434386656455d13714da_64) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Mezzanine Equity and Stockholders' Equity](#i8f8164e49047434386656455d13714da_67)</u> | [4](#i8f8164e49047434386656455d13714da_67) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Cash Flows](#i8f8164e49047434386656455d13714da_70)</u> | [5](#i8f8164e49047434386656455d13714da_70) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Notes to Consolidated Financial Statements](#i8f8164e49047434386656455d13714da_73)</u> | [7](#i8f8164e49047434386656455d13714da_73) - [37](#i8f8164e49047434386656455d13714da_145) |
| <u>[Item 2.](#i8f8164e49047434386656455d13714da_43)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i8f8164e49047434386656455d13714da_43)</u> | [38](#i8f8164e49047434386656455d13714da_43) |
| <u>[Item 3.](#i8f8164e49047434386656455d13714da_49)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i8f8164e49047434386656455d13714da_49)</u> | [53](#i8f8164e49047434386656455d13714da_49) |
| <u>[Item 4.](#i8f8164e49047434386656455d13714da_151)</u> | <u>[Controls and Procedures](#i8f8164e49047434386656455d13714da_151)</u> | [53](#i8f8164e49047434386656455d13714da_151) |
|  | <u>[PART II. OTHER INFORMATION](#i8f8164e49047434386656455d13714da_34)</u> |  |
| <u>[Item 1.](#i8f8164e49047434386656455d13714da_28)</u> | <u>[Legal Proceedings](#i8f8164e49047434386656455d13714da_28)</u> | [53](#i8f8164e49047434386656455d13714da_28) |
| <u>[Item 1A.](#i8f8164e49047434386656455d13714da_40)</u> | <u>[Risk Factors](#i8f8164e49047434386656455d13714da_40)</u> | [53](#i8f8164e49047434386656455d13714da_40) |
| <u>[Item 2.](#i8f8164e49047434386656455d13714da_37)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i8f8164e49047434386656455d13714da_37)</u> | [53](#i8f8164e49047434386656455d13714da_37) |
| <u>[Item 3.](#i8f8164e49047434386656455d13714da_154)</u> | <u>[Defaults Upon Senior Securities](#i8f8164e49047434386656455d13714da_154)</u> | [53](#i8f8164e49047434386656455d13714da_154) |
| <u>[Item 4.](#i8f8164e49047434386656455d13714da_151)</u> | <u>[Mine Safety Disclosures](#i8f8164e49047434386656455d13714da_31)</u> | [54](#i8f8164e49047434386656455d13714da_31) |
| <u>[Item 5.](#i8f8164e49047434386656455d13714da_166)</u> | <u>[Other Information](#i8f8164e49047434386656455d13714da_166)</u> | [54](#i8f8164e49047434386656455d13714da_166) |
| <u>[Item 6.](#i8f8164e49047434386656455d13714da_181)</u> | <u>[Exhibits](#i8f8164e49047434386656455d13714da_181)</u> | [54](#i8f8164e49047434386656455d13714da_181) |
| <u>[Signatures](#i8f8164e49047434386656455d13714da_187)</u> | <u>[Signatures](#i8f8164e49047434386656455d13714da_187)</u> | [57](#i8f8164e49047434386656455d13714da_187) |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**PART I - FINANCIAL INFORMATION**

**Item 1. - Financial Statements**

---

| |
|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** |
| **CONSOLIDATED BALANCE SHEETS** |

---

---

| | | |
|:---|:---|:---|
| | **March 31, 2026 (Unaudited)** | **December 31, 2025** |
| **ASSETS** | | |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $37209747 | $38112332 |
| &nbsp;&nbsp;Accounts receivable | 12260137 | 18082473 |
| &nbsp;&nbsp;Accounts receivable, related party | 13297909 | 9320103 |
| &nbsp;&nbsp;Income taxes receivable | 96224 | 411055 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 5453056 | 3646850 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 68317073 | 69572813 |
| &nbsp;&nbsp;Property and equipment, net | 1621754 | 1597896 |
| &nbsp;&nbsp;Intangible assets, net | 63284242 | 66360444 |
| &nbsp;&nbsp;Goodwill | 252779884 | 252779884 |
| &nbsp;&nbsp;Operating right-of-use assets | 10339573 | 4561692 |
| &nbsp;&nbsp;Management and performance fee receivable, related party | 14509188 | 14800140 |
| &nbsp;&nbsp;Life settlement policies, at fair value | 392770863 | 468857929 |
| &nbsp;&nbsp;Life settlement policies, at cost | 931353 | 918305 |
| &nbsp;&nbsp;Available-for-sale securities, at fair value; net of allowance for credit losses of $1,245,575 at March 31, 2026 and December 31, 2025 | 3147609 | 3108750 |
| &nbsp;&nbsp;Other investments | 20653585 | 18253585 |
| &nbsp;&nbsp;Other assets | 1439461 | 1428820 |
| **TOTAL ASSETS** | $829794585 | $902240258 |
| **LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY** |  |  |
| CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;Current portion of long-term debt, at fair value | $— | $114424000 |
| &nbsp;&nbsp;Current portion of long-term debt | 1500000 | 1500000 |
| &nbsp;&nbsp;Accrued expenses | 7146873 | 10935292 |
| &nbsp;&nbsp;Current operating lease liabilities | 1327873 | 720186 |
| &nbsp;&nbsp;Contract liabilities, deposits on pending settlements | 766528 | 169184 |
| &nbsp;&nbsp;Accrued transaction costs | 2200698 | 2336177 |
| &nbsp;&nbsp;Other current liabilities | 14092882 | 15853016 |
| &nbsp;&nbsp;Income taxes payable | 8767351 | 2653366 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 35802205 | 148591221 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| |
|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** |
| **CONSOLIDATED BALANCE SHEETS (CONT.)** |

---

---

| | | |
|:---|:---|:---|
| | **March 31, 2026 (Unaudited)** | **December 31, 2025** |
| &nbsp;&nbsp;Long-term debt, net | 275802521 | 275780392 |
| &nbsp;&nbsp;Long-term debt, at fair value | 38156705 |  |
| &nbsp;&nbsp;Long-term debt, related party | 14541873 | 14114199 |
| &nbsp;&nbsp;Retrocession fees payable | 5361714 | 5361714 |
| &nbsp;&nbsp;Noncurrent operating lease liabilities | 9985924 | 4637642 |
| &nbsp;&nbsp;Deferred tax liability | 27540858 | 30214160 |
| &nbsp;&nbsp;Warrant liability |  |  |
| **TOTAL LIABILITIES** | 407191800 | 478699328 |
| COMMITMENTS AND CONTINGENCIES (Note 12) |  |  |
| MEZZANINE EQUITY |  |  |
| Series A convertible preferred stock, $0.0001 par value; 5,000 shares authorized; 5,000 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 5000000 | 5000000 |
| **TOTAL MEZZANINE EQUITY** | 5000000 | 5000000 |
| STOCKHOLDERS' EQUITY |  |  |
| &nbsp;&nbsp;Preferred stock, $0.0001 par value; 1,000,000 shares authorized; 5,000 shares issued and outstanding |  |  |
| &nbsp;&nbsp;Class A common stock, $0.0001 par value; 200,000,000 authorized shares; 105,039,246 and 104,879,752 shares issued at March 31, 2026 and December 31, 2025, respectively | 10504 | 10488 |
| &nbsp;&nbsp;Treasury stock - at cost; 9,055,830 and 7,406,118 shares repurchased at March 31, 2026 and December 31, 2025, respectively | (70262583) | (55808595) |
| &nbsp;&nbsp;Additional paid-in capital | 522314870 | 515971485 |
| &nbsp;&nbsp;Accumulated deficit | (34460006) | (41632448) |
| &nbsp;&nbsp;Noncontrolling interest |  |  |
| **TOTAL STOCKHOLDERS' EQUITY** | 417602785 | 418540930 |
| **TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY** | $829794585 | $902240258 |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| |
|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** |
| **CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME** |
| **(Unaudited)** |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **REVENUES:** |  |  |
| &nbsp;&nbsp;Asset management | $1042443 | $748389 |
| &nbsp;&nbsp;Asset management, related party | 7416701 | 7024688 |
| &nbsp;&nbsp;Life solutions | 34016667 | 35397311 |
| &nbsp;&nbsp;Life solutions, related party | 16550621 | 901346 |
| &nbsp;&nbsp;Technology services | 363856 | 67612 |
| **TOTAL REVENUES** | 59390288 | 44139346 |
| **COST OF REVENUES (excluding depreciation and amortization stated below):** |  |  |
| &nbsp;&nbsp;Cost of revenue (including stock-based compensation) | 6307385 | 7108407 |
| **GROSS PROFIT** | 53082903 | 37030939 |
| **OPERATING EXPENSES:** |  |  |
| &nbsp;&nbsp;Sales and marketing | 4947910 | 2616000 |
| &nbsp;&nbsp;General and administrative (including stock-based compensation) | 25872125 | 12263786 |
| &nbsp;&nbsp;Gain on change in fair value of debt |  | (3362103) |
| &nbsp;&nbsp;Gain on equity securities, at fair value |  | (272254) |
| &nbsp;&nbsp;Depreciation and amortization expense | 3934086 | 4758546 |
| **TOTAL OPERATING EXPENSES** | 34754121 | 16003975 |
| **OPERATING INCOME** | 18328782 | 21026964 |
| **OTHER INCOME (EXPENSE):** |  |  |
| &nbsp;&nbsp;Loss on change in fair value of warrant liability |  | (4806000) |
| &nbsp;&nbsp;Interest expense | (10453592) | (9618330) |
| &nbsp;&nbsp;Interest income | 663223 | 1175001 |
| &nbsp;&nbsp;Other income (expense), net | 2518593 | (44524) |
| **TOTAL OTHER EXPENSE** | (7271776) | (13293853) |
| **NET INCOME BEFORE PROVISION FOR INCOME TAXES** | 11057006 | 7733111 |
| Income tax expense | 3790814 | 2334085 |
| **NET INCOME** | 7266192 | 5399026 |
| LESS: NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTEREST |  | 759443 |
| **NET INCOME ATTRIBUTABLE TO ABACUS GLOBAL MANAGEMENT, INC.** | $7266192 | $4639583 |
| **EARNINGS PER SHARE:** |  |  |
| &nbsp;&nbsp;Earnings per share - basic | $0.07 | $0.05 |
| &nbsp;&nbsp;Earnings per share - diluted | $0.07 | $0.05 |
| &nbsp;&nbsp;Weighted-average stock outstanding—basic | 96775889 | 96193199 |
| &nbsp;&nbsp;Weighted-average stock outstanding—diluted | 99545644 | 97498923 |
| **NET INCOME** | $7266192 | $5399026 |
| **COMPREHENSIVE INCOME BEFORE NON-CONTROLLING INTERESTS** | 7266192 | 5399026 |
| Net and comprehensive income attributable to non-controlling interests |  | 759443 |
| **COMPREHENSIVE INCOME ATTRIBUTABLE TO ABACUS GLOBAL MANAGEMENT, INC.** | $7266192 | $4639583 |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| |
|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** |
| **CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY** |
| **(Unaudited)** |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Series A Convertible Preferred Stock** | **Series A Convertible Preferred Stock** | **Class A Common Stock** | **Class A Common Stock** | **Treasury Stock** | **Treasury Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Non-<br>Controlling<br>Interests** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Non-<br>Controlling<br>Interests** | **Total<br>Stockholders'<br>Equity** |
| BALANCE AS OF DECEMBER 31, 2024 |  | $— | 96731194 | $10133 | (1048226) | $(12025137) | $494064113 | $(57896606) | $(857831) | $423294672 |
| Issuance of series A convertible preferred stock | 5000 | 5000000 |  |  |  |  |  |  |  |  |
| Repurchase of common stock |  |  |  |  |  |  |  |  |  |  |
| Stock-based compensation |  |  | 36000 | (456) |  |  | 2355852 |  |  | 2355396 |
| Warrant Conversions |  |  | 1134071 | 113 |  |  | (113) |  |  |  |
| Common stock issue costs |  |  |  |  |  |  | (470065) | (3) |  | (470068) |
| Issuance of common stock |  |  |  |  |  |  |  |  |  |  |
| Net income |  |  |  |  |  |  |  | 4639583 | 759443 | 5399026 |
| BALANCE AS OF MARCH 31, 2025 | 5000 | $5000000 | 97901265 | $9790 | (1048226) | $(12025137) | $495949787 | $(53257026) | $(98388) | $430579026 |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Series A Convertible Preferred Stock** | **Series A Convertible Preferred Stock** | **Class A Common Stock** | **Class A Common Stock** | **Treasury Stock** | **Treasury Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Non-<br>Controlling<br>Interests** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Non-<br>Controlling<br>Interests** | **Total<br>Stockholders'<br>Equity** |
| BALANCE AS OF DECEMBER 31, 2025 | 5000 | $5000000 | 104879752 | $10488 | (7406118) | $(55808595) | $515971485 | $(41632448) | $— | $418540930 |
| Repurchase of common stock |  |  |  |  | (1649712) | (14453988) |  |  |  | (14453988) |
| Stock-based compensation |  |  | 159494 | 16 |  |  | 6343385 |  |  | 6343401 |
| Dividends declared on the Series A Convertible Preferred Stock |  |  |  |  |  |  |  | (93750) |  | (93750) |
| Net income |  |  |  |  |  |  |  | 7266192 |  | 7266192 |
| BALANCE AS OF MARCH 31, 2026 | 5000 | $5000000 | 105039246 | $10504 | (9055830) | $(70262583) | $522314870 | $(34460006) | $— | $417602785 |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| |
|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** |
| **CONSOLIDATED STATEMENTS OF CASH FLOWS** |
| **(Unaudited)** |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Net income | $7266192 | $5399026 |
| &nbsp;&nbsp;Adjustments to reconcile net income to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3934086 | 4758546 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 6343401 | 2355396 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 864351 | 494130 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on other investments |  | (272254) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss (gain) on policies, at fair value | 35205286 | (27012517) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on change in fair value of debt |  | (3362103) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on change in fair value of warrant liability |  | 4806000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (2673302) | 1407048 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash interest income | (38859) | (37434) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash interest expense, related party | 427674 | 379539 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash interest expense |  | 117616 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash lease (benefit) expense | 178088 | (71554) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 5822336 | 9534488 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, related party | (3977806) | (399166) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management and performance fee receivable, related party | 290952 | 658021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (1806206) | (544528) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Investments | (2350000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (10641) | 273951 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (3788419) | (3382784) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued transaction costs | (135479) | (483206) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities, deposits on pending settlement | 597344 | (1873248) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | (1760134) | (5589233) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax payable | 6113984 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax receivable | 314833 | 152945 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retrocession fees payable |  | 49500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due from affiliates |  | (138985) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in life settlement policies, at fair value | 40881780 | (48796999) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in life settlement policies, at cost | (13048) | (12889) |

---

------

---

| |
|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** |
| **CONSOLIDATED STATEMENTS OF CASH FLOWS (CONT.)** |
| **FOR THE YEARS ENDED MARCH 31,** |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 91686413 | (61590694) |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment | (133891) | (224371) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of intangible assets | (747851) | (15032) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of other investments | (50000) | (3000000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of available for sale securities |  | (500000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (931742) | (3739403) |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of long term debt | 744367 | 16189871 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of discounts and financing costs | (682) | (156793) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of debt | (77853203) | (38415464) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issuance transaction costs |  | (470068) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (14453988) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of Series A Convertible Preferred dividend | (93750) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (91657256) | (22852454) |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (902585) | (88182551) |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 38112332 | 131944282 |
| CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | $37209747 | $43761731 |
| **NON-CASH OPERATING, INVESTING, AND FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Non-cash investment in other investments | $— | $5000000 |
| &nbsp;&nbsp;Non-cash issuance of series A convertible preferred stock |  | 5000000 |
| **SUPPLEMENTAL DISCLOSURES:** |  |  |
| &nbsp;&nbsp;Interest paid  | 9167637 | 5372786 |
| &nbsp;&nbsp; Unrealized gain on equity investments | 5400000 |  |
| &nbsp;&nbsp; Impairment loss on equity investments | (3050000) |  |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**ABACUS GLOBAL MANAGEMENT, INC.**

**CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**1. BASIS OF PRESENTATION**

The accompanying consolidated financial statements ("Interim Financial Statements") are presented in accordance with the rules and regulations of the United States ("U.S.") Securities and Exchange Commission ("SEC") and do not include all of the disclosures normally required by U.S. generally accepted accounting principles ("U.S. GAAP" or "GAAP") as contained in the Company's Annual Report on Form 10-K. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP. Accordingly, the Interim Financial Statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025 ("2025 Annual Report"). Refer to Note 2 in the Company's 2025 Annual Report for the full list of the Company's significant accounting policies. The details in those notes have not changed, except as discussed in Note 2 to the Interim Financial Statements and as a result of normal adjustments in the interim periods. Capitalized terms used and not specifically defined herein have the same meanings given to those terms in our 2025 Annual Report. We also may use certain other terms that are defined within these Interim Financial Statements.

The Interim Financial Statements presented herein and discussed below include 100% of the assets, liabilities, revenues, expenses, and cash flows of Abacus Global Management, Inc., (the "Company") all entities in which the Company has a controlling voting interest ("subsidiaries"), and variable interest entities ("VIEs") for which the Company is the primary beneficiary, as determined in accordance with consolidation accounting guidance. References in these Interim Financial Statements to net income or loss attributable to common stockholders and stockholders' equity do not include noncontrolling interests, which represent the outside ownership of our consolidated non-wholly owned entity and are reported separately. Intercompany accounts and transactions between consolidated entities have been eliminated in consolidation.

The Interim Financial Statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2025, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, the results of our operations, and cash flows for the periods presented. The Interim Financial Statements are not necessarily indicative of the results to be expected for the full year, or any other period. All references to financial information in the Interim Financial Statements and in the condensed notes to Interim Financial Statements are unaudited.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, cost of revenue, life settlement policy valuation, goodwill and intangibles valuation, and income taxes. The uncertainties in the broader macroeconomic environment have made it more challenging to make these estimates. Actual results could differ from our estimates, and such differences may be material.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**New Accounting Standards**—The Company's management reviews recent accounting standards to determine the impact to the Company's financial statements. There were no new accounting standard updates ("ASU") issued by the Financial Accounting Standards Board's ("FASB") in addition to those discussed in our 2025 Annual Report that would have an impact to the Interim Financial Statements.

***Recently Adopted Accounting Standards***

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**ASU 2025-05**—"Financial Instruments—Credit Losses (Topic 326): *Measurement of Credit Losses for Accounts Receivable and Contract Assets*". In July 2025, the FASB issued ASU 2025-05 to provide all entities with a practical expedient when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606. All entities may elect a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The Company adopted ASU 2025-05 on a prospective basis effective January 1, 2026. The Company elected the practical expedient to estimate expected credit losses for current accounts receivables. The election of the practical expedient provided by this ASU did not have an impact to the Company's consolidated financial statements upon adoption.

***Recently Issued Accounting Pronouncements* ASU 2025-11**—"Interim Reporting (Topic 270): *Narrow-Scope Improvements."* In December 2025, the FASB issued ASU 2025-11 to clarify interim disclosure requirements. The objective of the amendments is to provide further clarity about the current interim disclosure requirements. This ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Adoption of this ASU can be applied either using a prospective or a retrospective approach. Early adoption is permitted. The Company is currently evaluating the provisions of this ASU and does not expect this ASU to have a material impact on the Company's consolidated financial statements.

**Concentrations**—Two customers accounted for 13% (related party) and 14% (related party) in revenues related to sales of life insurance policies for the three months ended March 31, 2026. Three customers accounted for 13%, 12%, and 11% of in revenues related to sales of life policies for the three months ended March 31, 2025.

**Liquidity**—The first redemption date for LMA Income Series II, LP ("LMAIS II"), a limited partnership that is a variable interest entity in which the Company has invested was March 31, 2026 at which point the investors of that entity had the option to (i) redeem their investment, (ii) extend their investment for an additional year, or (iii) invest into an Abacus managed fund launched in March 2025. The next redemption date for LMAIS II will be June 30, 2027. As of March 31, 2026, the related remaining liabilities are included within long-term debt, at fair value within our consolidated balance sheet. Refer to Note 14, *Long-Term Debt* for additional information related to LMAIS II.

**Reclassifications**—Certain prior period amounts in these Interim Financial Statements and condensed notes have been reclassified to conform to the current presentation for the three months ended March 31, 2026 and as of the year ended December 31, 2025.

**3. BUSINESS COMBINATIONS**

**NIB Acquisition**

On April 24, 2025, the Company completed the acquisition of National Insurance Brokerage, LLC ("NIB"), a Delaware limited liability company (the "NIB Acquisition"). NIB was owned by Jay Jackson, Chief Executive Officer of the Company, who held a 25% beneficial interest in NIB, and KMG Group Holdings, LLC ("KMG"), who held a 75% beneficial interest in NIB (the "Sellers"). KMG is equally owned by Matthew Ganovsky, K. Scott Kirby, and Sean McNealy, Co-Founders and Presidents of the Company. The Company paid approximately $2.1 million in cash, net of cash acquired, to acquire 100% of the interest in NIB.

The NIB Acquisition was accounted for as a business combination in accordance with ASC 805, *Business Combinations* ("ASC 805"), which requires the Company to record the assets acquired and liabilities assumed at fair value as of the acquisition date. The values attributed to intangible assets were based on valuations prepared using Level 3 inputs and assumptions in accordance with ASC 820, *Fair Value Measurements* ("ASC 820").

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

Goodwill related to the NIB Acquisition was assigned to the Life Solutions reportable segment. It represents the value that we expect to obtain from growth opportunities from our combined operations and is deductible for tax purposes.

The Company finalized the valuations related to the acquired assets and liabilities of NIB on June 30, 2025. The following table presents the fair value of the assets acquired and the liabilities assumed in connection with the business combination.

---

| | |
|:---|:---|
| **Net Assets Identified** | **Fair Value (as finalized on June 30, 2025)** |
| Intangibles | $1393300 |
| Current Assets | 911478 |
| Deferred Tax Assets | 25388 |
| Accrued Expenses | (16908) |
| Net assets acquired | 2313258 |
| Goodwill | 686742 |
| &nbsp;&nbsp;**Total purchase price** | $3000000 |

---

Intangible assets were comprised of the following:

---

| | | | |
|:---|:---|:---|:---|
| **Asset Type** | **Fair Value** | **Useful Life** | **Valuation Methodology** |
| Customer relationships | $1393300 | 10 years | Multi-period excess earnings method |
| **Total fair value** | $1393300 |  |  |

---

**AccuQuote Acquisition**

On August 14, 2025 ("AccuQuote Acquisition Date"), the Company acquired 100% of Life Distributors, LLC ("AccuQuote"), a Delaware limited liability company ("AccuQuote Acquisition"). AccuQuote is an insurance brokerage firm. The Company used its note receivable balance of approximately $9.3 million due from AccuQuote as consideration as result of the AccuQuote's default on the note (non-cash consideration). The value of the note receivable balance on the AccuQuote Acquisition Date approximated fair value. The Company acquired approximately $0.3 million of cash and paid approximately $0.8 million in acquisition costs.

The Company evaluated whether the transaction should be accounted for as (i) a loan settlement within the scope of ASC 310-20-40-2 or (ii) a business combination within the scope of ASC 805. As part of the Company's evaluation of AccuQuote, the April 2025 financing was structured to provide the Company with creditor protections and an enforceable mechanism to obtain control upon the occurrence of defined events of default. Because the Company obtained control of AccuQuote by exercising a contractual call right upon an event of default as defined in the note agreement and acquiring 100% ownership, and because AccuQuote met the definition of a business (including inputs and processes capable of producing outputs), the Company concluded the transaction was a business combination under ASC 805. In addition, until the event of default and election to enforce remedies, AccuQuote remained independent and the Company held only creditor rights. Accordingly, the note receivable (including accrued amounts) was treated as consideration transferred in the acquisition rather than accounted for as a standalone loan settlement under ASC 310-20.

The Company assessed the note receivable prior to the acquisition date and concluded that no allowance for credit losses (ACL) was required and that the carrying amount approximated fair value on the acquisition date. In making these conclusions, the Company considered that (1) the note was secured by 100% of AccuQuote's assets, including its equity interests, and the Company's contractual remedies provided a recovery mechanism, (2) the default was related to specified financial covenant and financial metric noncompliance rather than an inability to generate cash flows, and (3) the Company did not

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

identify indicators of material operational deterioration through the default date. The Company also considered that the note was originated approximately 4.5 months prior to the acquisition on negotiated terms, and the Company's expected recovery under the note was supported by the secured structure and available remedies. The financing and related contractual remedies were designed to provide the Company with multiple paths to value realization—repayment under the note or, upon a defined event of default, the ability to obtain control through enforcement—consistent with the transaction's economic substance. Therefore, the Company concluded that the note's carrying value was approximately equal to its fair value at the time of acquisition.

The AccuQuote Acquisition was accounted for as a business combination in accordance with ASC 805, which requires the Company to record the assets acquired and liabilities assumed at fair value as of the acquisition date. The values attributed to intangible assets were based on valuations prepared using Level 3 inputs and assumptions in accordance with ASC 820.

Goodwill related to the AccuQuote Acquisition was assigned to the Life Solutions reportable segment. It represents the value that we expect to obtain from growth opportunities from our combined operations and is deductible for tax purposes.

The Company finalized the valuations related to the acquired assets and liabilities of AccuQuote, except for acquired receivables, accrued expenses, and other liabilities. Accordingly, these estimates are subject to change during the measurement period, which is up to one year from the AccuQuote Acquisition Date, as permitted under GAAP. Any potential adjustments could be material in relation to the values presented in the table below. No adjustments were made to the valuation for the period ended March 31, 2026.

The following table presents the fair value of the assets acquired and the liabilities assumed in connection with the business combination.

---

| | | | |
|:---|:---|:---|:---|
| **Net Assets Identified** | **Fair Value (as previously reported)** | **Adjustments** | **Adjusted Fair Value** |
| Intangibles | $3400000 | $— | $3400000 |
| Current Assets | 2061706 |  | 2061706 |
| Deferred Tax Assets | 164408 |  | 164408 |
| Accrued Expenses | (844798) |  | (844798) |
| Other Liabilities | (1906544) |  | (1906544) |
| Net assets acquired | 2874772 |  | 2874772 |
| Goodwill | 6390425 |  | 6390425 |
| &nbsp;&nbsp;**Total purchase price** | $9265197 | $— | $9265197 |

---

Intangible assets were comprised of the following:

---

| | | | |
|:---|:---|:---|:---|
| **Asset Type** | **Fair Value** | **Useful Life** | **Valuation Methodology** |
| Customer relationships | $2900000 | 10 years | Multi-period excess earnings method |
| Trade Name | 500000 | 3 years | Relief from royalty method |
| **Total fair value** | $3400000 |  |  |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**4. REVENUES**

**Disaggregated Revenue—**The disaggregation of the Company's revenue by major sources is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Asset management:** |  |  |
| &nbsp;&nbsp;Asset management fees, related party | $6656464 | $6698201 |
| &nbsp;&nbsp;Asset management fees | 987055 | 729010 |
| &nbsp;&nbsp;Servicing revenue, related party | 760237 | 326487 |
| &nbsp;&nbsp;Servicing revenue | 55388 | 19379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total asset management revenue | 8459144 | 7773077 |
| **Life solutions:** |  |  |
| &nbsp;&nbsp;Revenue from life insurance policies using the fair value method, net | 31462057 | 32933861 |
| &nbsp;&nbsp;Revenue from life insurance policies using the fair value method, related party, net | 16550621 | 901346 |
| &nbsp;&nbsp;Insurance commissions | 1630676 |  |
| &nbsp;&nbsp;Originations | 923934 | 2463450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total life solutions revenue | 50567288 | 36298657 |
| **Technology services:** |  |  |
| &nbsp;&nbsp;Technology services | 363856 | 67612 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total technology services revenue | 363856 | 67612 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $59390288 | $44139346 |

---

Further disaggregation of life solutions revenue:

---

| | |
|:---|:---|
| | **Three Months Ended March 31,** |
| | **2026** |
| **Life solutions:** |  |
| &nbsp;&nbsp;Realized gains from life insurance policies sold and matured using the fair value method | $4963066 |
| &nbsp;&nbsp;Premiums paid on sold and matured life insurance policies using the fair value method | (80356) |
| &nbsp;&nbsp;Premiums paid on life insurance policies held using the fair value method | (5852784) |
| &nbsp;&nbsp;Reversal of unrealized gains from prior quarters related to life insurance policies sold or matured using the fair value method | (10170472) |
| &nbsp;&nbsp;Unrealized gains from life insurance policies held using the fair value method | 42602603 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Revenue from life insurance policies using the fair value method, net** | **31462057** |
| &nbsp;&nbsp;Realized gains from life insurance policies sold and matured using the fair value method, related party | 87931646 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | |
|:---|:---|
| | **Three Months Ended March 31,** |
| | **2026** |
| &nbsp;&nbsp;Premiums paid on sold life insurance policies using the fair value method, related party | (3743608) |
| &nbsp;&nbsp;Reversal of unrealized gains from prior quarters related to life insurance policies sold and matured using the fair value method, related party | (67637417) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Revenue from life insurance policies using the fair value method, related party, net** | **16550621** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue for life insurance policies using the fair value method** | $**48012678** |

---

Refer to Note 19, *Related-Party Transactions* for additional information related to revenue from related parties.

**Asset Management Balances**—The Company has the following asset management related balances recorded within the following accounts in the consolidated balance sheets:

---

| | | |
|:---|:---|:---|
| **Balance Sheet Account** | **March 31, 2026** | **December 31, 2025** |
| **Management and Performance Fee Receivables:** | | |
| &nbsp;&nbsp;Accounts receivable, related party | $10134293 | $6718903 |
| &nbsp;&nbsp;Management and performance fee receivable, related party | 14509188 | 14800140 |
| &nbsp;&nbsp;Total management and performance fee receivables | $24643481 | $21519043 |
| **Retrocession Fee Payable:** |  |  |
| &nbsp;&nbsp;Other current liabilities | $5217445 | $4696788 |
| &nbsp;&nbsp;Retrocession fees payable | 5361714 | 5361714 |
| &nbsp;&nbsp;Total retrocession fees payable | $10579159 | $10058502 |

---

**Contract Balances**—We had no contract assets at March 31, 2026 and December 31, 2025. The balances of contract liabilities arising from originated contracts with customers were as follows:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Contract liabilities, deposits on pending settlements | $766528 | $169184 |
| &nbsp;&nbsp;Total contract liabilities | $766528 | $169184 |

---

Revenue recognized during the first quarter of 2026 that was included in our contract liabilities balance at December 31, 2025 was $169,184.

**5. LIFE SETTLEMENT POLICIES**

As of March 31, 2026, the Company held 659 life settlement policies, of which 656 were accounted for using the fair value method and 3 were accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value was $727,668,136 as of March 31, 2026, with a corresponding fair value of $392,770,863. The aggregate face value of policies accounted for using the investment method was $1,625,000 as of March 31, 2026, with a corresponding carrying value of $931,353. Differences between the face value and the net death benefit of certain policies is due to return of premium policies offset by loans on policies.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

As of December 31, 2025, the Company held 804 life settlement policies, of which 801 were accounted for under the fair value method and 3 were accounted for using the investment method (cost, plus premiums paid). The aggregate face value of policies held at fair value was $1,063,747,674 as of December 31, 2025, with a corresponding fair value of $468,857,929. The aggregate face value of policies accounted for using the investment method was $1,625,000 as of December 31, 2025, with a corresponding carrying value of $918,305.

At March 31, 2026, the Company did not have any contractual restrictions on its ability to sell policies, including those held as collateral for the issuance of long-term debt. Refer to Note 14, *Long-Term Debt* for further details.

Life expectancy reflects the probable number of years remaining in the life of a class of persons determined statistically, affected by such factors as heredity, physical condition, nutrition, and occupation.

There were no significant changes in the Company's expectation of the timing of the realization of revenues related to life settlement policies. Refer to Note 13, *Fair Value Measurements* for significant changes to the amounts disclosed related to life settlement policies.

**Policies Carried at Fair Value:**

The following tables summarize the Company's life insurance policies grouped by remaining life expectancy as of March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Remaining Life Expectancy (Years)** | **Policies** | **Face Value** | **Net Death Benefit** | **Fair Value** |
| 0-1 | 60 | $46982796 | $44994259 | $37731191 |
| 1-2 | 118 | 133401574 | 132000341 | 90727510 |
| 2-3 | 129 | 173112796 | 180300272 | 109728918 |
| 3-4 | 93 | 101302190 | 99159681 | 50559677 |
| 4-5 | 85 | 82922765 | 79927357 | 39457540 |
| Thereafter | 171 | 189946015 | 187410340 | 64566027 |
| Total | 656 | $727668136 | $723792250 | $392770863 |

---

The following tables summarize the Company's life insurance policies grouped by remaining life expectancy as of December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Remaining Life Expectancy (Years)** | **Policies** | **Face Value** | **Net Death Benefit** | **Fair Value** |
| 0-1 | 56 | $37289219 | $38364635 | $31591831 |
| 1-2 | 107 | 145413973 | 136961406 | 95037912 |
| 2-3 | 172 | 220587453 | 233422730 | 138986632 |
| 3-4 | 103 | 102158681 | 101592187 | 47674052 |
| 4-5 | 104 | 96790034 | 90018094 | 38562604 |
| Thereafter | 259 | 461508314 | 458781779 | 117004898 |
| Total | 801 | $1063747674 | $1059140831 | $468857929 |

---

**Policies Accounted for Using the Investment Method:**

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

The following tables summarize the Company's life insurance policies grouped by remaining life expectancy as of March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Remaining Life Expectancy (Years)** | **Policies** | **Face Value** | **Net Death Benefit** | **Carrying Value** |
| 4-5 | 1 | $750000 | $750000 | $455425 |
| Thereafter | 2 | 875000 | 898307 | 475928 |
|  | 3 | $1625000 | $1648307 | $931353 |

---

The following tables summarize the Company's life insurance policies grouped by remaining life expectancy as of December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Remaining Life Expectancy (Years)** | **Policies** | **Face Value** | **Net Death Benefit** | **Carrying Value** |
| 4-5 | 1 | $750000 | $750000 | $444987 |
| Thereafter | 2 | 875000 | 898307 | 473318 |
| Total | 3 | $1625000 | $1648307 | $918305 |

---

Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of March 31, 2026, are as follows:

---

| | |
|:---|:---|
| 2026 remaining | $39790 |
| 2027 | 53214 |
| 2028 | 11946 |
| Total | $104950 |

---

Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of December 31, 2025, are as follows:

---

| | |
|:---|:---|
| 2026 | $52837 |
| 2027 | 53214 |
| 2028 | 11946 |
| &nbsp;&nbsp;Total | $117997 |

---

The Company is required to pay premiums to keep its portion of life insurance policies in force. The estimated total future premium payments could increase or decrease significantly to the extent that actual mortalities of insureds differ from the estimated life expectancies.

For policies accounted for under the investment method, the Company has not been made aware of information causing a material change to assumptions relating to the timing of realization of life insurance settlement proceeds that would impact the carrying value of policies.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**6. PROPERTY AND EQUIPMENT—NET**

Property and equipment balances are composed of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Computer equipment | $1935923 | $1802032 |
| Furniture and fixtures | 232349 | 232349 |
| Leasehold improvements | 153780 | 153780 |
| Property and equipment—gross | 2322052 | 2188161 |
| Less: accumulated depreciation | (700298) | (590265) |
| Property and equipment—net | $1621754 | $1597896 |

---

Depreciation expense for the three months ended March 31, 2026 and 2025, was $110,033 and $66,826, respectively.

**7. GOODWILL AND OTHER INTANGIBLE ASSETS**

Goodwill of $252,779,884 was recognized as a result of the business combinations, which represent the excess fair value of consideration over the fair value of the underlying net assets. Refer to Note 3, *Business Combinations* for further discussion.

The changes in the carrying amount of goodwill by reportable segments were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reportable Segment** | **December 31, 2025** | **Additions** | **Adjustments** | **March 31, 2026** |
| Life Solutions | $147007357 | $— | $— | $147007357 |
| Asset Management | 105772527 |  |  | 105772527 |
| Total | $252779884 | $— | $— | $252779884 |

---

Intangible Assets Acquired comprised of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asset Type** | **Net Book Value** | **Useful Life** | **Weighted Average Remaining Amortization Period** | **Valuation Methodology** |
| Management agreements | $47400000 | 4 - 8 years | 3.8 years | Multi-period excess-earnings method |
| Customer relationships | 31693300 | 3 - 10 years | 2.2 years | Multi-period excess-earnings method |
| Non-compete agreements | 7400000 | 1 - 3 years | 0.1 years | With or Without Method |
| Internally developed and used technology | 2100000 | 2 - 3 years | 0.0 years | Replacement Cost Method |
| Trade Name | 2500000 | 3 - 10 years | 0.3 years | Relief from Royalty Method |
| State Insurance Licenses | 2700000 | Indefinite |  | Replacement Cost Method |
| Trade Name | 900000 | Indefinite |  | Relief from Royalty Method |
|  | $94693300 |  | 6.4 years |  |

---

Intangible assets and related accumulated amortization as of March 31, 2026 are as follows:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Gross Value** | **Accumulated Amortization** | **Net Book Value** |
| **Definite Lived Intangible Assets:** | | | |
| Management agreements | $47400000 | $11116825 | $36283175 |
| Customer relationships | 31693300 | 12732800 | 18960500 |
| Non-compete agreements | 7400000 | 6122222 | 1277778 |
| Internally developed and used technology | 2100000 | 1869445 | 230555 |
| Trade Name | 2500000 | 377778 | 2122222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $91093300 | $32219070 | $58874230 |
| **Indefinite Lived Intangible Assets:** |  |  |  |
| State Insurance Licenses | 2700000 |  | 2700000 |
| Trade Name | 900000 |  | 900000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $94693300 | $32219070 | $62474230 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Gross Value** | **Accumulated Amortization** | **Net Book Value** |
| **Definite Lived Intangible Assets:** | | | |
| Management agreements | $47400000 | $9032419 | $38367581 |
| Customer relationships | 31693300 | 11335052 | 20358248 |
| Non-compete agreements | 7400000 | 5930556 | 1469444 |
| Internally developed and used technology | 2100000 | 1827777 | 272223 |
| Trade Name | 2500000 | 286111 | 2213889 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $91093300 | $28411915 | $62681385 |
| **Indefinite Lived Intangible Assets:** |  |  |  |
| State Insurance Licenses | 2700000 |  | 2700000 |
| Trade Name | 900000 |  | 900000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $94693300 | $28411915 | $66281385 |

---

All intangible assets with finite useful lives are subject to amortization when they are available for their intended use. Amortization expense for definite-lived intangible assets was $3,824,053 and $4,633,154 for the three months ended March 31, 2026 and 2025, respectively.

Estimated future amortization of definite-lived intangible assets as of March 31, 2026 is as follows:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | |
|:---|:---|
| 2026 remaining | $11404795 |
| 2027 | 15014728 |
| 2028 | 11501255 |
| 2029 | 7813616 |
| 2030 | 5999171 |
| Thereafter | 7140665 |
| &nbsp;&nbsp;Total | $58874230 |

---

The Company also had other insignificant intangible assets of $810,012 and $79,059 as of March 31, 2026 and December 31, 2025, respectively.

**8. AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE**

**Convertible Promissory Note**—The Company holds investments in convertible promissory notes in two separate unrelated entities ("Convertible Promissory Notes") for an initial investment of $1,000,000 each. The first note bore an annual interest rate of 8% and matured on September 30, 2025. The unrelated entity that was due to repay the first convertible promissory note on September 30, 2025, stopped operations in August 2025. The Company does not believe that it will be able to recover its investment in this convertible note and related accrued interest, and has recorded an estimated 100% credit loss as of December 31, 2025, and as of March 31, 2026, which includes the accrued interest. The second note bears an annual interest rate of 5% and matures on October 15, 2028. During 2025, the Company acquired an additional interest in the second note of $2,000,000, for a total principal investment of $3,000,000.

The Company applies the available-for-sale method of accounting for its investments in the Convertible Promissory Notes, which are debt investments. The Convertible Promissory Notes do not qualify for either the held-to-maturity method due to the Convertible Promissory Notes' conversion rights or the trading securities method because the Company holds the Convertible Promissory Notes as long-term investments. The Convertible Promissory Notes are measured at fair value at each reporting period-end. As of March 31, 2026 and December 31, 2025, fair value was $3,147,609 and $3,108,750, which includes accrued accumulated non-cash interest income of $393,184 and $354,325, respectively.

There were no credit losses recognized for the three months ended March 31, 2026 and 2025.

The following tables provide a rollforward of the allowance for credit losses on available-for-sale securities for the three months ended March 31, 2026 and March 31, 2025:

---

| | |
|:---|:---|
| | **Convertible Promissory Notes** |
| Balance at December 31, 2025 | $1245575 |
| &nbsp;&nbsp;Current period provision for expected credit losses |  |
| &nbsp;&nbsp;Write-offs charged against the allowance |  |
| &nbsp;&nbsp;Recoveries of amounts previously written off |  |
| Balance at March 31, 2026 | $1245575 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | |
|:---|:---|
| | **Convertible Promissory Notes** |
| Balance at December 31, 2024 | $— |
| &nbsp;&nbsp;Current period provision for expected credit losses |  |
| &nbsp;&nbsp;Write-offs charged against the allowance |  |
| &nbsp;&nbsp;Recoveries of amounts previously written off |  |
| Balance at March 31, 2025 | $— |

---

Interest income recognized for the three months ended March 31, 2026 and 2025 was $38,859 and $37,434, respectively.

**9. OTHER INVESTMENTS AND OTHER ASSETS**

**Other Investments**—The Company owns convertible preferred and common stock in three and four unrelated entities as of March 31, 2026 and December 31, 2025, respectively. The value of the combined investment was $20,653,585 and $18,253,585 as of March 31, 2026 and December 31, 2025, respectively.

For the three months ended March 31, 2026, the Company impaired an investment by $3,050,000 in one equity investment. The Company received notification that the entity has begun the process to wind down the business due to a failed business sale. This impairment is recorded within Other income (expense), net in the consolidated statements of operations and comprehensive income.

For the three months ended March 31, 2026, the Company recorded a $5,400,000 unrealized gain on one equity investment. The entity had a new capital raise during the period, increasing the underlying value of the investment. This capital raise was considered an orderly transaction in the same equity class as the initial investment, representing the intrinsic value in this investee's business. The unrealized gain is recorded within Other income (expense), net in the consolidated statements of operations and comprehensive income.

For the three months ended March 31, 2025, the Company acquired $3,000,000 convertible preferred stock and $5,000,000 of common stock in two separate unrelated entity, respectively. The investment of $5,000,000 in common stock was purchased by the Company issuing series A convertible preferred stock. Refer to Note 15, *Convertible Preferred Stock and Stockholders' Equity* for further information.

The Company applies the measurement alternative for its investments in the common stock and convertible preferred stock because these investments are of an equity nature, and the Company does not have the ability to exercise significant influence over operating and financial policies of entities even in the event of conversion of preferred stock. Under the measurement alternative, the Company records the investment based on original cost, less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the investee. The Company's share of income or loss of such companies is not included in the Company's consolidated statements of operations and comprehensive income. The Company tests its investments for impairment whenever circumstances indicate that the carrying value of the investment may not be recoverable.

**Other Assets***—*The Company's other assets are composed of the following:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Restricted cash deposits in compliance with various regulations | $1439461 | $1428820 |
| &nbsp;&nbsp;**Total other assets** | $1439461 | $1428820 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**10. CONSOLIDATION OF VARIABLE INTEREST ENTITIES**

The Company consolidates VIEs for which it is the primary beneficiary or VIEs for which it controls through a majority voting interest or other arrangement. See Note 2, *Summary of Significant Accounting Policies* of our 2025 Annual Report, for more information on how the Company evaluates an entity for consolidation in accordance with ASC 810, *Consolidation* ("ASC 810").

The Company evaluated any entity in which it had a variable interest upon formation to determine whether the entity should be consolidated. The Company also evaluated the consolidation conclusion during each reconsideration event, such as changes in the governing documents or additional equity contributions to the entity. During the three months ended March 31, 2026, the Company's consolidated VIE, LMA Income Series II LP, had total assets of $123,556,607 and liabilities of $38,458,866. For the year ended December 31, 2025, the Company's consolidated VIEs, LMA Income Series II LP, LMX Series LLC (LMATT Series 2024, Inc.), and LMA Income Series, LP, had total assets and liabilities of $204,604,881 and $115,186,408. The Company did not deconsolidate any entities during the three months ended March 31, 2026, or year ended December 31, 2025. Refer to Note 14, *Long-Term Debt* for information related to the classification of assets and liabilities.

Carlisle manages collective portfolios of several Luxembourg alternative investment funds investing in life insurance policies. Carlisle is registered as an authorized alternative investment fund manager ("AIFM") by Luxembourg's Commission de Surveillance du Secteur Financier ("CSSF"). Carlisle manages three funds and eight sub-funds. The funds and sub-funds managed by Carlisle are collectively referred to as the "Carlisle Funds". The Company, through LMA, services the life insurance policies held by the Carlisle Funds. The Company concluded that it does not have a controlling financial interest in the Carlisle Funds pursuant to ASC 810-10. Accordingly, the Carlisle Funds are not consolidated in the Company's financial statements. The management fee arrangement is the only interest in the funds and the fees are customary and commensurate, therefore not providing a variable interest in the funds. As a result, all transactions between the Company and the Carlisle Funds, including life policy purchases and sales, servicing fees, and management fee receivables are classified as related party transactions. Refer to Note 4, *Revenues* and Note 19, *Related-Party Transactions* for additional information.

The Company established Abacus Enhanced Income Fixed LP, Abacus Enhanced Income Plus LP, Abacus Premiere Income Fixed LP, and Abacus Premiere Income Plus LP (collectively the "LP Funds") and respective wholly owned general partner entities for the purpose of managing the LP Funds and servicing the policies invested by the LP Funds. The Company concluded that it does not have a controlling financial interest in the LP Funds pursuant to ASC 810-10. Accordingly, the LP Funds are not consolidated in the Company's financial statements. It was determined that the Company's management has significant influence over the significant activities of the unconsolidated LP Funds through contract but does not have significant economic interest through equity or otherwise. As a result, all transactions between the Company and the LP Funds, including life policy purchases and sales, servicing fees, and management fee receivables are classified as related party transactions. Refer to Note 4, *Revenues* and Note 19, *Related-Party Transactions* for additional information.

The Company established 2025 LMA LLC ("Securitized Entity") for the purpose of providing investors with a pool of life policies through a sale of life policies and to serve as static collateral pool to secure their investment in a promissory note issued by the Securitized Entity. The Company, through its LMA subsidiary, services the static collateral pool. The Company is a Class B member with contributed capital of $8,699,569, representing all of the nonvoting economic interest in the Securitized Entity. The Class A member has all of the voting noneconomic interest in the Securitized Entity. The Class A member has substantive power to remove the Company as the servicer of the Securitized Entity. The Company concluded that it was not the primary beneficiary in the Securitized Entity due to lack of power pursuant to ASC 810. Accordingly, the Securitized Entity is not consolidated in the Company's financial statements. It was determined that while the Company's management does not have the authority to establish

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

policies or make significant decision impacting the Securitization Fund, it is serving as the servicer for the securitized static collateral pool under the direct supervision of an independent manger. As a result, life policy sales and fee revenue earned by LMA from the Securitized Entity is presented as related party servicing revenue in the Company's consolidated financial statements. Refer to Note 4, *Revenues* and Note 19, *Related-Party Transactions* for additional information.

**11. SEGMENT REPORTING**

The Company organizes its business into three reportable segments (1) Asset Management, (2) Life Solutions, and (3) Technology Services, which all generate revenue and incur expenses in different manners.

This segment structure reflects the financial information and reports used by the Company's management, specifically its chief operating decision maker (CODM), to make decisions regarding the Company's business, including resource allocations and performance assessments, as well as the current operating focus in compliance with ASC 280, *Segment Reporting* ("ASC 280"). The Company's CODM is the President and Chief Executive Officer.

The Asset Management segment generates revenues by providing asset management services primarily to institutional investors alongside private clients investing in uncorrelated, and longevity-based assets, fixed-income replacement strategies and free cash flow based investment solutions. The revenue is determined by the asset management agreements with the individual investment vehicles. It also generates revenues by providing policy servicing activities to customers on a contract basis.

The Life Solutions segment generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner. The policies are purchased from owners or other providers through advisors, brokers, or directly through the owner.

The Technology Services segment generates revenues by providing real-time mortality verification, missing participant verification, and other services specific to the life insurance market services to customers on a contract basis.

The Company's method for measuring profitability on a reportable segment basis is gross profit. The CODM does not review disaggregated assets by segment due to segment assets not being necessary for resource allocation decisions. The Company's CODM periodically reviews cost of revenues by segment and treats it as a significant segment expense.

Revenue related to the Company's reportable segments is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Asset management | $8459144 | $7773077 |
| Life solutions | 50567288 | 36298657 |
| Technology services | 363856 | 67612 |
| &nbsp;&nbsp;**Total revenue** | $59390288 | $44139346 |

---

Cost of revenue (including stock-based compensation) related to the Company's reportable segments is as follows:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Asset management | $2595978 | $2742018 |
| Life solutions | 3085681 | 3900859 |
| Technology services | 625726 | 465530 |
| &nbsp;&nbsp;**Total cost of revenue (including stock-based compensation)** | $6307385 | $7108407 |

---

Gross profit related to the Company's reportable segments and the reconciliation of the total gross profit to net income is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Asset management | $5863166 | $5031059 |
| Life solutions | 47481607 | 32397798 |
| Technology services | (261870) | (397918) |
| &nbsp;&nbsp;**Total gross profit** | $53082903 | $37030939 |
| Sales and marketing | (4947910) | (2616000) |
| General and administrative (including stock-based compensation) | (25872125) | (12263786) |
| Depreciation and amortization expense | (3934086) | (4758546) |
| Other income (expense), net | 2518593 | (44524) |
| Loss on change in fair value of warrant liability |  | (4806000) |
| Interest expense | (10453592) | (9618330) |
| Interest income | 663223 | 1175001 |
| Gain (loss) on change of fair value of debt |  | 3362103 |
| Unrealized gain (loss) on investments |  | 272254 |
| Income tax expense | (3790814) | (2334085) |
| Less: Net (income) loss attributable to non-controlling interest |  | (759443) |
| &nbsp;&nbsp;**NET INCOME ATTRIBUTABLE TO ABACUS GLOBAL MANAGEMENT, INC.** | $7266192 | $4639583 |

---

Segment gross profit is defined as revenues less cost of sales, excluding depreciation and amortization. Expenses below the gross profit line are not allocated across operating segments, as they relate primarily to the overall management of the consolidated entity.

Revenue by geographic location:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| United States | $52929682 | $33457048 |
| Luxembourg | 6400287 | 7926034 |
| Other | 60320 | 2756264 |
| &nbsp;&nbsp;**Total revenue** | $59390289 | $44139346 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**12. COMMITMENTS AND CONTINGENCIES**

**Legal Proceedings**—Occasionally, the Company may be subject to various proceedings such as lawsuits, disputes, claims, or challenges to life insurance policy acquisitions. The Company assesses these proceedings as they arise and accrues a liability when losses are probable and reasonably estimable. Although legal proceedings are inherently unpredictable, the Company is currently not aware of any matters that, if determined adversely to the Company, would individually, or taken together, have a material adverse effect on the Company's business, financial position, results of operations, or cash flows.

**Investment Acquisition**—On March 12, 2026, the Company announced a $52.9 million acquisition of a minority position in Manning & Napier, an asset management and wealth advisory firm to further its strategic goals. This transaction is expected to close in the second quarter of 2026 subject to customary closing conditions, including regulatory approvals.

**13. FAIR VALUE MEASUREMENTS**

The Company determines fair value based on assumptions that market participants would use in pricing an asset or a liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 inputs: Other than quoted prices in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

**Recurring Fair Value Measurements**—The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are presented in the tables below. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and or other relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ materially from management's estimates.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value Hierarchy** | **Fair Value Hierarchy** | **Fair Value Hierarchy** | **Fair Value Hierarchy** |
| **As of March 31, 2026** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Life settlement policies, at fair value | $— | $— | $392770863 | $392770863 |
| Total assets held at fair value | $— | $— | $392770863 | $392770863 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Long-term debt, at fair value | $— | $— | $38156705 | $38156705 |
| Total liabilities held at fair value: | $— | $— | $38156705 | $38156705 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value Hierarchy** | **Fair Value Hierarchy** | **Fair Value Hierarchy** | **Fair Value Hierarchy** |
| **As of December 31, 2025** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Life settlement policies, at fair value | $— | $— | $468857929 | $468857929 |
| Total assets held at fair value | $— | $— | $468857929 | $468857929 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Current portion of long-term debt, at fair value | $— | $— | $114424000 | $114424000 |
| Total liabilities held at fair value: | $— | $— | $114424000 | $114424000 |

---

**Life Settlement Policies*—*** The Company accounts for owned life settlement policies using the fair value method or investment method (cost, plus premiums paid). The valuation method is chosen upon contract acquisition and is irrevocable.

The Company purchases policies from individuals or institutions, bundles those policies into tranches and sells to institutions, insurance carriers or funds that are attracting new investors. These initial purchases happen in the secondary market and the tertiary market. The secondary market is different from the principal or most advantageous market for purchasing policies and has less competition due to state-by-state licensing requirements. The Company leverages its broad policy base and extensive network, to offer individual policies that provide enhanced standalone value. This is achieved by precisely matching each policy's risk profile to the specific needs of fund managers, institutions, insurance carriers, or funds as well as bundling secondary market originated policies with those originated in the tertiary market. This tailored approach attracts new investors by making it easier to identify and acquire policies that align with their investment objectives. This approach enhances realized gains because it increases market liquidity, broadens the investor base, and enables more efficient price discovery, which in turn supports higher policy values. Our historical realized gains on policies sold and matured, are materially consistent regardless of where policies are originated.

For policies carried at fair value, the valuation is based on Level 3 inputs that reflect our assumptions about what factors market participants would use in pricing the asset. Fair value is determined using a discounted cash flow ("DCF") with Monte Carlo simulation to determine the fair value of each policy. The Company's model uses a discount rate based on observed transaction pricing which is assessed against historical realized gains. The valuation process uses significant assumptions, including survival probabilities and mortality assumptions informed by third-party life expectancy reports and a base mortality table (SOA 2015 VBT) adjusted via a mortality rating to match the risk-adjusted life expectancy, and market-calibrated discount rates.

The Monte Carlo simulation is applied to each policy to generate one million mortality scenario simulations which provides a comprehensive distribution of potential outcomes and calculates expected cash flows. In certain circumstances, if there is a verbal commitment to purchase a specific policy as of the balance sheet date, we use that transaction price as the fair value as we believe it is a more precise estimate of exit price than that determined using historical data. Further information about the inputs to the valuation are listed below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risk-Based Discount Rate: Each policy's discount rate is determined based on its proprietary risk score (1-5 scale), with discount rates directly calibrated to observed transaction prices for policies in the same risk score category. Specifically, for each risk score category, the Company calculates the annualized internal rate of return ("IRR") implied by the relationship between modeled future cash flows (based on life expectancies) and the actual sales price observed in a dataset comprising over 1,000 executed policy transactions. These implied IRRs are aggregated on a weighted-average basis by risk score category to establish the discount rates applied in the Company's DCF/Monte Carlo valuation model. The dataset is updated periodically and adjusted for current market conditions

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

based on observed institutional demand and contemporaneous trade activity. This transaction-based approach ensures that discount rates reflect actual transaction pricing rather than theoretical market rates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risk Score: Each policy is assigned a proprietary risk score from 1 to 5, with 5 being higher risk, based on multiple factors including insured age, life expectancy, life expectancy extension ratio, survival probability at breakeven, maturity probability, and risk-adjusted return on capital metrics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Life expectancy: Survival curves are generated using the Society of Actuaries 2015 VBT mortality tables adjusted by mortality ratings to achieve risk-adjusted life expectancies. For policies with multiple insureds, joint survival probabilities are calculated using statistical modeling techniques.

Related party considerations: To assess if related party sales are transacted at market terms, each policy is assessed against independent market checks, including indications from unaffiliated third parties, comparisons to third-party executed sales for policies with comparable characteristics (e.g.; Risk Score and Life Expectancy), and verifying that the terms and customary approval processes are consistent with those offered to non-related parties.

The Company performs quarterly lookback analysis to validate current valuations against actual market transactions. The quarterly lookback reviews policies sold and matured during the current quarter and compares sale prices to fair value measures as of the prior quarter. Discount rates are derived from observed transaction pricing and modeled cash flows, historical realized gains are used, if at all, as a reasonableness check rather than an adjustment factor.

*Risk Metrics and Portfolio Analysis*

Expected Tail Loss ("ETL99"): The Company calculates Expected Tail Loss at the 99th percentile, representing the weighted average of net present values in the worst 1% of simulated scenarios. This metric is used in conjunction with average net present value ("NPV") to derive Risk-Adjusted Return on Capital ("RAROC") ratios for individual policies and portfolio-level risk assessment.

Portfolio Diversification: When evaluating policies as part of a portfolio, the Company performs correlated analysis across all holdings, recognizing that combining policies with varying risk profiles can mitigate tail risk exposure while maintaining expected returns.

Data Sources: Valuations are fundamentally based on historical realized gains analysis from over one thousand policy transactions, representing actual transaction-based IRRs by risk category. Current market conditions are incorporated through ongoing discussions with investors such as institutional asset managers, credit unions, regional banks, and reinsurers, and proprietary risk modeling developed from the Company's transaction history.

The following table provides quantitative information about significant unobservable inputs for Level 3 fair value measurements as of March 31, 2026:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fair Value** | **Valuation Technique** | **Significant Unobservable Inputs** | **Weighted Average** | **Range** |
| **Life insurance polices:** | **Life insurance polices:** | | | |
| $392770863 | Discounted cash flow with Monte Carlo simulation | Discount rate | 10% | 10% —11% |
|  |  | Life expectancy (months) | 39 months | 1 month —265 months |
|  |  | Risk score | 2.25 | 1 —5 |
| **Secured borrowing, at fair value:** | **Secured borrowing, at fair value:** |  |  |  |
| $38156705 | Discounted cash flow | Discount rate | 8.4% | 8.0% — 8.5% |

---

The following table provides quantitative information about significant unobservable inputs for Level 3 fair value measurements as of December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fair Value** | **Valuation Technique** | **Significant Unobservable Inputs** | **Weighted Average** | **Range** |
| **Life insurance polices:** | **Life insurance polices:** | | | |
| $468857929 | Discounted cash flow with Monte Carlo simulation | Discount rate | 13% | 13% —15% |
|  |  | Life expectancy (months) | 45 months | 1 month —267 months |
|  |  | Risk score | 2.16 | 1 —5 |

---

The reduction in the weighted average discount rate from 13% as December 31, 2025 to 10% as of March 31, 2026 reflects observed market trade spreads.

For life settlement policies carried using the investment method, the Company measures these at the cost of the policy plus premiums paid. The policies accounted for using the investment method totaled $931,353 at March 31, 2026 and $918,305 at December 31, 2025, respectively.

**Discount Rate Sensitivity**—10% was determined to be the weighted average discount rate used to estimate the fair value of policies held by the Company and its investment funds. If the discount rate increased or decreased by one percentage point and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of March 31, 2026, would be as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Fair Value** | **Change in <br>Fair Value** | **Implied Realized Gain** |
| +1% | $385694793 | (7076070) | 22% |
| No change | 392770863 |  | 24% |
| -1% | $409128486 | 16357623 | 29% |

---

**Historical Realized Gains Sensitivity**—While the weighted average discount rate can fluctuate based on the overall mix of policies included in the company's portfolio at any given time, the discount rates are determined using historical realized gains by risk category, which have a more consistent weighted average. As a result, we have supplementally added an additional sensitivity analysis for realized gains. The fair value of life settlement policies is sensitive to changes in key unobservable inputs used to estimate the fair value of policies held by the Company and its investment funds. The historical realized gains represents the total actual sales price of policies less their total cost basis divided by their total cost basis. The sensitivity analysis is intended to illustrate the potential increase or decrease if policies sold for

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

an average of 1% above or below their determined sale price. The fair market value of the Company's policies would increase when historical realized gains on life insurance policies sold increases. If the historical realized gains increased or decreased by one percentage point and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of March 31, 2026, would be as follows:

---

| | | |
|:---|:---|:---|
| | **Fair Value** | **Change in <br>Fair Value** |
| +1% | $395142114 | $2371251 |
| No change | 392770863 |  |
| -1% | $388819840 | $(3951023) |

---

**Credit Exposure to Insurance Companies**—The following table provides information about the life insurance issuer concentrations that exceed 10% of total face value or 10% of total fair value of the Company's life insurance policies as of March 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
| **Carrier** | **Percentage of<br>Face Value** | **Percentage of<br>Fair Value** | **Carrier**<br>**Rating**<sup>1</sup> |
| Transamerica | 14.8% | 16.1% | A |
| Lincoln National Life Insurance Company | 12.1% | 13.5% | A |

---

<sup>1</sup> Carrier ratings are based on AM Best ratings.

The following table provides a rollforward of the fair value of life insurance policies for the three months ended March 31, 2026 and March 31, 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Balance, beginning of period | $468857929 | $370398447 |
| Policies purchased<sup>1</sup> | 156739049 | 105633081 |
| Matured/sold policies<sup>2</sup> | (197620829) | (56836082) |
| Unrealized gain on held policies and reversal of prior quarter unrealized gain on policies sold and matured | (35205286) | 27012517 |
| Balance, end of period | $392770863 | $446207963 |

---

<sup>1</sup> Policies purchased represents life insurance policies purchased during the period.

<sup>2</sup> Matured/sold policies represents life insurance policies held at the beginning of the period and those purchased during the period that also matured or were sold within the period.

The following table provides a reconciliation of revenue from life insurance policies held using the fair value method for the three months ended March 31, 2026 and March 31, 2025:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Gains or losses recognized in life solutions revenue in the consolidated statements of operations and comprehensive income:** | **2026** | **2025** |
| &nbsp;&nbsp;Realized gain on matured/sold policies | $92894712 | $15130764 |
| &nbsp;&nbsp;Premiums paid | (9676748) | (8308074) |
| &nbsp;&nbsp;Unrealized gain on held policies and reversal of prior quarter unrealized gain on policies sold and matured | (35205286) | 27012517 |
| Revenue from life insurance policies held using the fair value method | $48012678 | $33835207 |

---

 **Long-Term Debt**—See Note 14, *Long-Term Debt* for additional information on the secured borrowing. The Company has elected the fair value option in accounting for the long-term debt. Fair value is determined using Level 3 inputs.

**Available-for-Sale Investment**—The convertible promissory notes are classified as an available-for-sale securities. Available-for-sale investments are subsequently measured at fair value. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. The Company determines fair value of its available-for-sale investments using unobservable inputs by considering the initial investment value, next round financing, and the likelihood of conversion or settlement based on the contractual terms in the agreement. As of March 31, 2026 and December 31, 2025, the Company evaluated the fair value of its Convertible Promissory Notes and determined that the fair value approximates the carrying value of $3,147,609 and $3,108,750, respectively. Refer to Note 9, *Other Investments and Other Assets* for additional information.

**Non-Recurring Fair Value Measurements**

**Other Investments**— These investments are recorded at cost under the ASC 321 measurement alternative and are adjusted for impairment and observable price changes. Impairment is assessed qualitatively. As of March 31, 2026, and December 31, 2025, the Company determined that the carrying value of $20,653,585 and $18,253,585, respectively. Refer to Note 9, *Other Investments and Other Assets* for additional information.

**Financial Instruments Where Carrying Value Approximates Fair Value**—The carrying value of cash and cash equivalents, accounts receivables, accounts receivable, related party, income tax receivables, accrued expenses, and other current liabilities approximates fair value due to the short-term nature of their maturities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14.LONG-TERM DEBT**

Outstanding principal balances of Long-term debt comprises of the following:

---

| | | | |
|:---|:---|:---|:---|
| | **Maturity Date** | **March 31, 2026** | **December 31, 2025** |
| **Secured borrowing:** | | | |
| &nbsp;&nbsp;Senior Secured Credit Facility | December 10, 2030 | 148500000 | 148875000 |
| &nbsp;&nbsp;Deferred issuance costs and discounts |  | (3509434) | (3655384) |
| **Secured borrowing, at fair value:** |  |  |  |
| &nbsp;&nbsp;LMA Income Series II, LP | June 30, 2027 | 38156705 | 114890540 |
| &nbsp;&nbsp;Deferred issuance costs |  |  | (466540) |
| **Unsecured borrowing:** |  |  |  |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Maturity Date** | **March 31, 2026** | **December 31, 2025** |
| &nbsp;&nbsp;Fixed Rate Senior Unsecured Notes | November 15, 2028 | 135379475 | 135379475 |
| &nbsp;&nbsp;Sponsor PIK Note | July 5, 2028 | 14541873 | 14114199 |
| &nbsp;&nbsp;Deferred issuance costs and discounts |  | (3067520) | (3318699) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total debt |  | 330001099 | 405818591 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less current portion of long-term debt |  | (1500000) | (115924000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt |  | $328501099 | $289894591 |

---

**Fixed Rate Senior Unsecured Notes**

The Company issued fixed rate senior unsecured notes ("Fixed Unsecured Notes") between 2023 and 2025. The Fixed Unsecured Notes are based on a fixed interest rate of 9.875% to be paid in quarterly interest payments and mature on November 15, 2028. The Company has the option to redeem the Fixed Unsecured Notes in whole or in part at a price of 100% of the outstanding principal balance on or after February 15, 2027. The notes will be senior unsecured obligations of the Company and will rank equal in right of payment to all of the Company's other senior unsecured indebtedness from time to time outstanding. As of March 31, 2026, the balance outstanding on the Fixed Unsecured Notes was $135,379,475.

**Senior Secured Credit Facility**

On December 10, 2024 (the "Senior Secured Credit Facility Closing Date" or "SSCF Closing Date"), the Company entered into a Credit Agreement (the "Senior Secured Credit Facility" or "SSCF"), among the Company, as borrower, and affiliates of Sagard Senior Lending Partners Holdings II LP and Värde Partners, as lenders, and other persons from time to time party thereto (the "SSCF Lenders"), and GLAS USA LLC, as Administrative Agent and Collateral Agent for the SSCF Lenders thereunder. The SSCF provided credit extensions for (i) an initial term loan in an aggregate principal amount of $100,000,000 upon the closing of the SSCF and (ii) optional delayed draw term loans in an aggregate principal amount of up to $50,000,000 that are available for 180 days after the SSCF Closing Date ("DDTL Facility"), subject to the requirement that on each delayed draw date, the proceeds are used for operations, including the purchase of life settlement policies, to support its overall business strategy, for working capital purposes, and for general corporate purposes, which may include funding previously announced and future acquisitions and repayment and refinancing of its indebtedness. The SSCF and any drawn amounts under the DDTL Facility mature on December 10, 2030, with quarterly amortization payments of (i) 1.00% per annum of the aggregate principal amount of the initial facility outstanding as of the SSCF Closing Date and DDTL Facility to the extent borrowed and (ii) additional amortization payments based on the Company's Consolidated Adjusted EBITDA, in each case with the remaining outstanding principal amount due on the maturity date.

The interest rate is based an adjusted term Secured Overnight Financing Rate ("SOFR"), which was calculated as term SOFR plus a fixed rate of 5.25% per annum with a stepdown to 5.00% if the Company achieves certain metrics related to Consolidated Adjusted EBITDA and Total Leverage Ratios. In addition, undrawn amounts committed under the Delayed Draw Facility bear a commitment fee until such commitments are drawn or cancelled. The loan may be prepaid at any time in amounts of $1.0 million or greater, subject to a premium equal to 1.00% of the amount prepaid if prepaid prior to the 12-month anniversary of funding.

The Company drew the full amount available in the DDTL facility in September 2025.

The SSCF contains customary covenants for financings of this type including financial maintenance and restrictive covenants, such as the aggregate asset value held at the loan parties to the sum of the outstanding principal amounts of the loans. The SSCF restricts the payment of dividends and distributions and the ability of the Company to make certain investments, incur certain indebtedness and liens and sell

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

assets, in each case subject to important exceptions. The SSCF also includes various financial covenants, each measured on a quarterly basis, including (A) a maximum Secured Leverage Ratio (as defined in the SSCF Credit Agreement), (B) a minimum Consolidated Fixed Charge Coverage Ratio (as defined in the SSCF Credit Agreement), and (C) a minimum Asset Coverage Ratio (as defined in the SSCF Credit Agreement). In addition, the SSCF Credit Agreement includes customary events of default, including failure to pay interest or principal in a timely manner, failure to comply with covenants, cross-defaults to other material indebtedness, certain bankruptcy related events and subject to certain threshold and notices requirements as set forth in the Credit Agreement. The Company is in compliance with its debt covenants as of March 31, 2026.

In connection with the SSCF, certain wholly owned and material subsidiaries of the Company issued a guaranty with respect to the obligations of the Company under the SSCF Credit Agreement and related documents (the "SSCF Credit Facility Guaranty"), which excludes the assets of LMA Income Series II, LP. Additionally, the Company and the guarantors party to the SSCF Credit Facility Guaranty entered into a security agreement (the "SSCF Credit Facility Security Agreement"), which secures the SSCF Credit Facility on primarily all assets of the Company and each guarantor on a first lien basis to the exclusion of certain Excluded Assets (as defined in the SSCF Credit Agreement), including the life insurance policies owned by the Company and each Guarantor.

**LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing**

On January 31, 2023, LMA Income Series II, GP, LLC, wholly owned and controlled by that LMA Series, LLC ("LMA"), formed a limited partnership, LMA Income Series II, LP ("LMAIS II"), and subsequently issued partnership interests to limited partners in a private placement offering. The initial term of the offering was three years ending on March 31, 2026 with the ability to extend for two additional one-year periods ending on June 30, 2027 and on December 31, 2028. The limited partners receive annual dividends equal to the Preferred Return Amounts as follows: Capital commitment of less than $500,000, 8.00%; between $500,000 and $1,000,000, 8.25%; and over $1,000,000, 8.50%. Thereafter, 100% of the excess are to be paid to the General Partner.

It was determined that LMA is the primary beneficiary of LMAIS II and thus has fully consolidated the limited partnership in its consolidated financial statements.

The private placement offerings proceeds are used to acquire and actively manage a large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA recognizes the proceeds received from the offering as a secured borrowing.

For the three months ended March 31, 2026 and 2025, LMA Income Series II GP LLC, through the LMAIS II, admitted $744,367 and $16,189,871 additional limited partnership interests and redeemed $77,478,203 and $11,751,343 existing limited partnership interests, respectively.

LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of March 31, 2026, the fair value of the secured borrowing includes long-term debt ($38,156,705) and other liabilities ($302,161), respectively. LMAIS II is secured by its assets, which includes cash ($9,931,726), accounts receivable ($6,589,119), life settlement policies

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

($106,926,040), and other assets ($89,973) totaling $123,536,858 as of March 31, 2026. The asset coverage ratio is 3.24x as of March 31, 2026.

**Sponsor PIK Note**

On June 30, 2023, in connection with the Merger Agreement, East Sponsor, LLC, a Delaware limited liability company ("Sponsor"), made an unsecured loan to the Company in the aggregate amount of $10,471,648 (the "Sponsor PIK Note") with an interest rate of 12.0% per year compounding semi-annually. Accrued interest is payable in arrears quarterly starting on September 30, 2023 by adding it to the outstanding principal balance. As of March 31, 2026 and December 31, 2025, $4,070,225 and $3,642,551 in non-cash interest expense was added to the outstanding principal balance, respectively. The Sponsor PIK Note matures on June 30, 2028 and may be prepaid at any time in accordance with its terms without any premium or penalty. Non-cash Interest expense recognized for the three months ended March 31, 2026 and 2025 was $427,674 and $379,539, respectively.

Maturities of long-term debt (secured and unsecured) outstanding, including current maturities, excluding unamortized debt issuance costs, as of March 31, 2026 are as follows:

---

| | |
|:---|:---|
| **Years** | **Amount** |
| 2026 remaining | $1125000 |
| 2027 | 39656705 |
| 2028 | 151421348 |
| 2029 | 1500000 |
| 2030 | 142875000 |
| &nbsp;&nbsp;Total | $336578053 |

---

**15. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY**

The Company is authorized to issue up to 200,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. 5,000 shares of preferred stock are issued or outstanding. Holders of the Company's common stock are entitled to one vote for each share. As of March 31, 2026, there were 105,039,246 shares of common stock issued, of which 95,983,416 are outstanding and 9,055,830 shares were held in treasury stock. As of December 31, 2025, there were 104,879,752 shares of common stock issued, of which 97,473,634 were outstanding and 7,406,118 shares were held in treasury stock. Holders of shares were entitled to receive, in the event of a liquidation, dissolution or winding up, ratably the assets available for distribution to the stockholders after payment of all liabilities.

**Preferred Stock**

On March 18, 2025, the Company's Board of Directors authorized the issuance and the Company issued 5,000 shares of Series A Convertible Preferred Stock with a $5,000,000 aggregate liquidation preference in in a private placement transaction. The outstanding shares of Series A Convertible Preferred Stock are classified as mezzanine equity due to the holder redemption rights upon change of control, which was determined to be outside of the Company's control. Key terms include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Dividends: 7.5% annual rate on the $1,000 per share liquidation preference, payable in cash or in-kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ranking: Senior to common stock for dividends and liquidation rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Redemption: Company may redeem after March 18, 2028 (3 years after issuance).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Change of Control: Holders can require repurchase upon a Change of Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Conversion: Initial conversion rate of 100 shares of common stock per $1,000 of liquidation preference, subject to anti-dilution adjustments.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Maturity: No stated maturity; remains outstanding indefinitely unless redeemed, repurchased, or converted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Voting Rights: Holders generally vote on an as-converted basis with common stock.

**Stock Repurchase Program**

Occasionally, the Company's Board of Directors approves stock repurchase programs. Stock repurchases may be made through open market transactions, block trades, accelerated stock repurchases, privately negotiated transactions, derivative transactions or otherwise, certain of which may be made pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, in compliance with applicable state and federal securities laws. The timing, as well as the number and value of stock repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including our assessment of the intrinsic value of the Company's common stock, the market price of the Company's common stock, general market and economic conditions, available liquidity, compliance with the Company's debt and other agreements, applicable legal requirements, the nature of other investment opportunities available to the Company, and other considerations. The Company is not obligated to purchase any stock under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases by using cash on hand and expected free cash flow to be generated in the future. Acquired shares of our common stock are held as treasury stock carried at cost in our consolidated financial statements. In connection with the repurchase program, the Company is authorized to adopt one of more plans pursuant to the provisions of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

On December 11, 2023, the Company's Board of Directors authorized a stock repurchase program under which the Company may purchase shares of our common stock for an aggregate purchase price not to exceed $15,000,000 over a period of up to 18 months.

On April 9, 2025, on June 5, 2025, November 6, 2025, and January 30, 2026 the Company's Board of Directors authorized the Company to repurchase up to an additional $15,000,000, $20,000,000, $10,000,000, and $20,000,000, respectively, expiring in May 2027.

As of March 31, 2026, $9,737,417 remained available for repurchase under the stock repurchase programs.

The following tables summarize stock repurchase activity under our stock repurchase program for the periods ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Total Number of Shares Purchased** | **Cost of Shares Repurchased** | **Average Price Paid per Share** |
| As of December 31, 2025 | 7406118 | $55808595 | $7.54 |
| &nbsp;&nbsp;January 1, 2026 to January 31, 2026 | 533414 | 4508979 | 8.46 |
| &nbsp;&nbsp;February 1, 2026 to February 28, 2026 | 515892 | 4254340 | 8.28 |
| &nbsp;&nbsp;March 1, 2026 to March 31, 2026 | 600406 | 5690669 | 9.50 |
| As of March 31, 2026 | 9055830 | $70262583 | $8.25 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Total Number of Shares Purchased** | **Cost of Shares Repurchased** | **Average Price Paid per Share** |
| As of December 31, 2024 | 1048226 | $12025137 | $11.61 |
| &nbsp;&nbsp;January 1, 2025 to January 31, 2025 |  |  |  |
| &nbsp;&nbsp;February 1, 2025 to February 28, 2025 |  |  |  |
| &nbsp;&nbsp;March 1, 2025 to March 31, 2025 |  |  |  |
| As of March 31, 2025 | 1048226 | $12025137 | $11.61 |

---

**16. STOCK-BASED COMPENSATION**

***Long-term Incentive Plan***

The Company awards restricted stock units ("RSUs") to executives, employees, and directors as part of the Company's Long-Term Equity Compensation Incentive Plan ("Long-term Incentive Plan" or "LTIP"). This plan provides that equity-based awards, including RSUs, performance stock units ("PSU"), stock options, and unrestricted shares of common stock, may be granted to officers, employees, and directors of the Company. The Company has granted RSUs that provide the right to receive, subject to service based vesting conditions, shares of common stock pursuant to the Long-term Incentive Plan. The expense associated with these awards will be based on the fair value of the stock as of the grant date, where the Company elected to use the straight line recognition over the vesting period, which is three years. Under the approved Long-term Incentive Plan, generally, each RSU entitles the unit holder to one share of common stock when the restriction expires. After satisfying the above vesting conditions, the participants will be fully entitled to their shares of common stock. Shares that are issued upon vesting are newly issued shares from the Long-term Incentive Plan and are not issued from treasury stock. Forfeitures are recorded as they occur and are made available for subsequent awards.

The following table shows a summary of the unvested restricted stock under the Long-Term Incentive Plan as of March 31, 2026 as well as activity during the year:

---

| | | |
|:---|:---|:---|
| | **Number of shares** | **Weighted Average Grant Date Fair Value** |
| Restricted stock units, unvested, December 31, 2025 | 4460325 | $7.36 |
| Granted | 1362152 | 8.65 |
| Vested | (249594) | 8.58 |
| Forfeited | (413793) | 5.32 |
| Restricted stock units, unvested, March 31, 2026 | 5159090 | $7.80 |

---

After the approved amendment to the Long-Term Incentive Plan, 26,783 shares of common stock remained available for issuance.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

Black-Scholes option-pricing model assumptions and the resulting fair value of options on grant date are presented in the following table:

---

| | |
|:---|:---|
| | **Stock Options on Grant Date** |
| Dividend yield | —% |
| Expected volatility | 23.00% |
| Risk-free interest rate | 3.98% |
| Expected option life | 5.81 years |
| Weighted average fair value of stock options | $3.91 |

---

At the time of the award, the Company did not intend to pay dividends for the foreseeable future. The expected volatility reflects the Company's past daily common stock price volatility. The risk-free interest rate is derived using the term matched U.S. Treasury constant maturity yields. The expected stock option life is based on the average of the average time to vest and the remaining contractual term.

The following table shows the status of, and changes in, common stock options:

---

| | | |
|:---|:---|:---|
| | **Number of Stock Options** | **Weighted Average Exercise Price** |
| Options outstanding, December 31, 2025 | 345263 | $12.37 |
| &nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;Exercised |  |  |
| &nbsp;&nbsp;Expired or cancelled |  |  |
| Options exercisable, March 31, 2026 | 345263 | $12.37 |

---

**Summary of Stock-Based Compensation Expense**

Compensation costs recognized for RSUs and stock options were $6,343,401 and $2,355,395 for the three months ended March 31, 2026 and 2025, respectively.

For the three months ended March 31, 2026 and 2025, $671,669 and $485,319 of the compensation costs was recorded in cost of revenue (including stock-based compensation) in the consolidated statements of operations and comprehensive income, respectively. For the three months ended March 31, 2026 and 2025, $5,671,732 and $1,870,076 of the compensation costs is recorded in general and administrative expense (including stock-based compensation) in the consolidated statements of operations and comprehensive income, respectively.

As of March 31, 2026, there was approximately $31,823,238 of unrecognized compensation costs related to RSUs and stock options which the Company expects to recognize over the next 2.1 years.

**17. EMPLOYEE BENEFIT PLAN**

The Company has a defined contribution plan in the U.S. intended to qualify under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer up to 100% of their annual compensation on a pretax basis. The Company matches up to a maximum of 4% of eligible employee contributions and may choose to make additional discretionary contributions to the 401(k) Plan. For the three months ended March 31, 2026 and 2025, the Company recognized expenses related to the

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

401(k) Plan amounting to $401,438 and $118,123, respectively. For the three months ended March 31, 2026 and 2025, the Company did not make discretionary contributions.

**18. INCOME TAXES**

For the three months ended March 31, 2026 and 2025, the Company recorded a provision for income taxes of $3,790,814 and $2,334,085, respectively. The effective tax rate is 34.3% for the three months ended March 31, 2026 primarily driven by the increase in net income. The effective rate for the three months ended March 31, 2025 was 30.2% due to the impact of stock-based compensation expense deduction limited by the Internal Revenue Code (IRC) Section 162(m) and the impact of the VIEs.

The Company did not have any unrecognized tax benefits relating to uncertain tax positions at March 31, 2026, and December 31, 2025, and did not recognize any interest or penalties related to uncertain tax positions at March 31, 2026, and December 31, 2025. The Company does not anticipate that changes in its unrecognized tax benefits will have a material impact on the consolidated statements of operations and comprehensive income during 2026.

**19. RELATED-PARTY TRANSACTIONS**

The Sponsor PIK Note payable of $14,541,873 is recorded as a related-party transaction given the relationship between the Sponsor and the Company. Refer to Note 14, *Long-Term Debt* for more information.

Life policy sales to the Carlisle Funds, LP Funds, and the Securitized Entity are considered related party activity. Life policy purchases from the Carlisle or LP Funds are also considered related party activity. In addition, management fees, performance fees, servicing fees and certain expense reimbursement from the Carlisle Funds, LP Funds, and Securitized Entity are considered related party transactions. The servicing fee charged to the Carlisle Funds, LP Funds, and Securitized Entity is $1,000 per policy per year, $996 per policy per year, and 100 basis points of the value of the collateral pool per year, respectively. The Company charges a management fee to the Carlisle and LP funds that range between fifty and two hundred basis points of AUM divided by 12.

As of March 31, 2026, the Company had $13,297,909 and $14,509,188 current and noncurrent related party receivables due from the related party funds, respectively. As of December 31, 2025, the Company had $9,320,103 and $14,800,140 current and noncurrent related party receivables due from related party funds, respectively. As of March 31, 2026, the current related-party receivable balance was mainly comprised of $10,134,293 and $1,172,514 from the Carlisle Funds related to management fees and policy sales, respectively. As of December 31, 2025, the current related-party receivable balance was mainly comprised of $6,718,903 and $2,055,170 from the Carlisle Funds related to management fees and policy sales, respectively. All noncurrent related party receivables are due from the Carlisle Funds.

The Company may at times purchase life policies with different risk characteristics and risk profiles from the Carlisle Funds or LP Funds for life solutions revenue purposes. For the three months ended March 31, 2026, the Company paid $825,366 to acquire policies from the Carlisle Funds. For the three months ended March 31, 2025, the Company did not acquire policies from the LP Funds.

For the three months ended March 31, 2026 and 2025, the Company recognized $6,656,464 and $6,698,201 in asset management fees from the related party funds, respectively, as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended,** | **Three months ended,** |
| | **March 31, 2026** | **March 31, 2025** |
| Carlisle Funds | $5766184 | $6698201 |
| LP Funds | 890280 |  |
| &nbsp;&nbsp;Total | $6656464 | $6698201 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

For the three months ended March 31, 2026 and 2025, the Company recognized $16,550,621 and $901,346 in net revenue from life policy sales to the Carlisle and LP, respectively. The $16,550,621 revenue for the three months ended March 31, 2026 was a result of realized gains on sales of $87,931,646, offset by the reversals of prior period unrealized gains of $67,637,417 and premiums paid during the period of $3,743,608. The revenue $901,346 for the three months ended March 31, 2025 was a result of realized gains on sales of $901,346.

---

| | | |
|:---|:---|:---|
| | **Three months ended,** | **Three months ended,** |
| | **March 31, 2026** | **March 31, 2025** |
| Carlisle Funds | $187965 | $901346 |
| LP Funds | 16362656 |  |
| &nbsp;&nbsp;Total | $16550621 | $901346 |

---

For the three months ended March 31, 2026 and 2025, the Company recognized $760,237 and $326,487 in servicing revenue from related parties, respectively. Refer to Note 10, *Consolidation of Variable Interests* for additional information on consolidation considerations for the Carlisle, LP, and Securitization Entity. Refer to Note 2, *Summary of Significant Accounting Policies* within the 2025 Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for additional information discussing the Company's revenue recognition polices for transactions with the Carlisle, LP, and Securitization Entity.

**20. LEASES**

In February 2026, the Company entered into a new lease for office space ("2026 Office Lease"). The Company recognized a lease right of use asset and lease liability related to the 2026 Office Lease increasing the Company's right of use asset and liability by $6,123,131. The lease terminates at the end of December 2030 with no substantive option to extend or terminate the 2026 Office Lease beyond the term of the lease.

The Company's right-of-use assets and lease liabilities for its operating lease consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Assets: |  |  |
| &nbsp;&nbsp;Operating lease right-of-use assets | $10339573 | $4561692 |
| Liabilities: |  |  |
| &nbsp;&nbsp;Operating lease liability, current | 1327873 | 720186 |
| &nbsp;&nbsp;Operating lease liability, non-current | 9985924 | 4637642 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease liability | $11313797 | $5357828 |

---

The Company recognizes lease expense for its operating leases within general, administrative, and other expenses on the Company's consolidated statements of operations and comprehensive income. The Company's lease expense for the periods presented consisted of the following:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Operating lease cost | $516638 | $179143 |
| Variable lease cost | 18680 | 25150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease cost | $535318 | $204293 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

The following table shows supplemental cash flow information related to lease activities for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Cash paid for amounts included in the measurement of the lease liability: |  |  |
| Operating cash outflows for operating leases | $328243 | $323911 |
| ROU assets obtained in exchange for new lease liabilities | 6123131 |  |

---

The table below shows a weighted-average analysis for lease terms and discount rates for all operating leases for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Weighted-average remaining lease term (in years) | 5.19 | 6.72 |
| Weighted-average discount rate | 7.20% | 9.78% |

---

Future minimum noncancellable lease payments under the Company's operating leases on an undiscounted basis reconciled to the respective lease liability at March 31, 2026 are as follows:

---

| | |
|:---|:---|
| | **Operating leases** |
| 2026 remaining | $1370520 |
| 2027 | 2731026 |
| 2028 | 2820627 |
| 2029 | 2913362 |
| 2030 | 2213823 |
| Thereafter | 1362138 |
| Total operating lease payments (undiscounted) | 13411496 |
| Less: Imputed interest | (2097699) |
| Lease liability as of March 31, 2026 | $11313797 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21. EARNINGS PER SHARE**

Basic earnings per share represents net income attributable to stockholders divided by the weighted average number of common stock outstanding during the reported period. Treasury stock is excluded from the weighted average number of shares of common stock outstanding. Diluted earnings per share is computed by giving effect to all potential weighted average dilutive common stock. For diluted earnings per share, the dilutive effect of outstanding awards is reflected by application of the treasury stock method and convertible securities by application of the if converted method, as applicable.

The table below illustrates the reconciliation of the earnings and number of shares used in our calculation of basic earnings per share attributable to common stockholders:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net income | $7266192 | $5399026 |
| &nbsp;&nbsp;Less: net (income) loss attributable to noncontrolling interest |  | (759443) |
| &nbsp;&nbsp;Less: dividends declared on the series A convertible preferred stock | (93750) |  |
| Net income attributable to common stockholders for basic earnings per share | 7172442 | 4639583 |
| Weighted average shares outstanding for basic earnings per share | 96775889 | 96193199 |
| Basic earnings per share | $0.07 | $0.05 |

---

The table below illustrates the reconciliation of the earnings or loss and number of shares used in our calculation of diluted earnings or loss per share attributable to common stockholders:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net income attributable to common stockholders for basic earnings per share | 7172442 | 4639583 |
| Numerator used to calculate diluted earnings per share | 7172442 | 4639583 |
| Weighted average shares outstanding for basic earnings per share | 96775889 | 96193199 |
| Effect of dilutive shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;RSUs | 2269755 | 1227946 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series A preferred stock | 500000 | 77778 |
| Weighted average shares for diluted earnings per share | 99545644 | 97498923 |
| Diluted earnings per share | $0.07 | $0.05 |

---

The following potentially dilutive outstanding securities were excluded from the computation of diluted net earnings per share because their effect would have been anti-dilutive for the periods presented, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period:

---

| | |
|:---|:---|
| | **Three Months Ended March 31,** |
| | **2026** |
| RSUs | 13223 |
| Stock Options | 147316 |
| Total | 160539 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22. SUBSEQUENT EVENTS**

The Company evaluated subsequent events and transactions from the consolidated balance sheet date through the date at which the consolidated financial statements were issued. Based upon the review, management did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

\*\*\*\*\*

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Cautionary Note Regarding Forward-Looking Statements**

*The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations, hopes, intentions or strategies regarding the future. In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading "Cautionary Note Regarding Forward-Looking Statements." All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to: the potential impact of our business relationships, including with our employees, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; weakness or adverse changes in the level of activity in our sector or the sectors of our affiliated companies, which may be caused by, among other things, high or increasing interest rates, or a weak U.S. economy; significant competition that our operating subsidiaries face; compliance with extensive government regulation; and other risks detailed in the those set forth under "Risk Factors" or elsewhere in this quarterly statement and in our 2025 Annual Report on Form 10-K. Unless the context otherwise requires, references in this "Abacus Global Management, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations" to "we," "us," "our," , "Abacus", and "Company" are intended to mean the business and operations of Abacus Global Management, Inc.*

*The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the Company's financial condition and results of operations. This discussion should be read in conjunction with the Company's financial statements and related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and our 2025 Annual Report on Form 10-K.*

***Business Overview***

The Company is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide. We serve as the originator and market maker of the assets we purchase and manage, providing a distinct advantage for consumers seeking to monetize insurance policies and for investors seeking to deploy capital. In a highly regulated and difficult-to-access insurance marketplace, we provide consumers with the maximum opportunity for their insurance assets and we also provide investors with a high-quality class of assets.

***Performance Measures***

NM - Not Meaningful.

***Results of Operations for the Three Months Ended March 31, 2026 and March 31, 2025***

The following tables set forth our results of operations for the periods presented. The period-to-period comparison of financial results is not indicative of future results:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **REVENUES:** |  |  |
| &nbsp;&nbsp;Asset management | $8459144 | $7773077 |
| &nbsp;&nbsp;Life solutions | 50567288 | 36298657 |
| &nbsp;&nbsp;Technology services | 363856 | 67612 |
| **TOTAL REVENUES** | 59390288 | 44139346 |
| **COST OF REVENUES (excluding depreciation and amortization stated below):** |  |  |
| &nbsp;&nbsp;Cost of revenue (including stock-based compensation) | 6307385 | 7108407 |
| **GROSS PROFIT** | 53082903 | 37030939 |
| **OPERATING EXPENSES:** |  |  |
| &nbsp;&nbsp;Sales and marketing | 4947910 | 2616000 |
| &nbsp;&nbsp;General and administrative (including stock-based compensation) | 25872125 | 12263786 |
| &nbsp;&nbsp;Gain on change in fair value of debt |  | (3362103) |
| &nbsp;&nbsp;Gain on equity securities, at fair value |  | (272254) |
| &nbsp;&nbsp;Depreciation and amortization expense | 3934086 | 4758546 |
| **TOTAL OPERATING EXPENSES** | 34754121 | 16003975 |
| **OPERATING INCOME** | 18328782 | 21026964 |
| **OTHER INCOME (EXPENSE):** |  |  |
| &nbsp;&nbsp;Loss on change in fair value of warrant liability |  | (4806000) |
| &nbsp;&nbsp;Interest expense | (10453592) | (9618330) |
| &nbsp;&nbsp;Interest income | 663223 | 1175001 |
| &nbsp;&nbsp;Other income (expense), net | 2518593 | (44524) |
| **TOTAL OTHER EXPENSE** | (7271776) | (13293853) |
| **NET INCOME BEFORE PROVISION FOR INCOME TAXES** | 11057006 | 7733111 |
| Income tax expense | 3790814 | 2334085 |
| **NET INCOME** | 7266192 | 5399026 |
| LESS: NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTEREST |  | 759443 |
| **NET INCOME ATTRIBUTABLE TO ABACUS GLOBAL MANAGEMENT, INC.** | $7266192 | $4639583 |

---

**Revenue**

***Asset Management***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Asset management fees, related party | $6656464 | $6698201 | $(41737) | (0.6)% |
| Asset management fees | 987055 | 729010 | 258045 | 35.4% |
| Servicing revenue, related party | 760237 | 326487 | 433750 | 132.9% |
| Servicing revenue | 55388 | 19379 | 36009 | 185.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total asset management revenue** | $8459144 | $7773077 | $686067 | 8.8% |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

Asset management revenue increased by $686,067, or 8.8%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The increase is mainly due to an increase in servicing revenue driven by increases in policies in LP Funds. The Company did not record significant performance fees during the three months ended March 31, 2026. Refer to the *Assets Under Management* section below for the change in total assets managed and refer to the *Key Business Metrics* below for the average management fees charged.

***Life Solutions***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Revenue from life insurance policies using the fair value method, net | $31462057 | $32933861 | $(1471804) | (4.5)% |
| Revenue from life insurance policies using the fair value method, related party, net | 16550621 | 901346 | 15649275 | 1736.2% |
| Insurance commissions | 1630676 |  | 1630676 | NM |
| Originations | 923934 | 2463450 | (1539516) | (62.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total life solutions revenue** | $50567288 | $36298657 | $14268631 | 39.3% |

---

Total life solutions revenue increased by $14,268,631 or 39.3% for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The increase is mainly due to an increase in the number of policies sold and realized gain recognized on policies sold. The higher sales generated $77,763,948 in total realized gains on sold life policies, partially offset by a decrease of $62,217,803 in total unrealized gains, and a decrease of $1,368,674 in total premiums paid.

The Company considers (i) independent market checks where available (including bids/indications from unaffiliated third parties and third-party investor interest in the same or similar policies), (ii) comparisons to contemporaneous third-party executed sales for policies with comparable characteristics (including Risk Score and other key attributes), and (iii) parity of key non-price terms and customary execution/approval processes to confirm the related-party transactions are consistent with those offered to non-related parties.

The realized and unrealized gain activity is mainly due to the Company's expanded available capital in 2026 compared to early 2025 and deployment capacity following the launching of Abacus managed funds in March 2025 and the $50 million delayed draw financing in September 2025. The average realized gain per policy sold also improved, rising from 21.0% for the three months ended March 31, 2025 to 26.4% for the three months ended March 31, 2026. This reflects increased institutional demand for life settlement policies as uncorrelated assets, creating more favorable pricing conditions for the Company's portfolio trades. During the three months ended March 31, 2026, the Company sold approximately 41% of the policies that were on the balance sheet as of December 31, 2025 and redeployed a majority of that capital to purchase additional policies. In the quarter ended March 31, 2026, the Company's weighted average discount rate was 10%, which is based on risk score and is directly calibrated to observed transaction prices for policies in the same risk score category. Refer to Note 4, *Revenues* and Note 13, *Fair Value Measurements* for additional information on the composition of revenue from life insurance policies. The combination of realized gains (loss) (sale price less purchase price) less premiums paid on sold/matured policies during the corresponding period and the reversal of the prior period unrealized gain on sold/matured policies represents the incremental gain (loss) on policies held using the fair value method for the corresponding reporting period from sales or maturities to related and unrelated parties (maturity gains are part of unrelated revenues).

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

The decrease to origination revenue is primarily due to the Company originating policies for LMA and LMAIS II, rather than for third parties, and origination fees associated with LMA and LMAIS II are eliminated in consolidation.

The Company began generating insurance commissions revenue after April 2025 after acquiring NIB and AccuQuote in August 2025. Refer to Note 3, *Business Combinations* for additional information.

***Technology Services***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Technology services | $363856 | $67612 | $296244 | 438.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total technology services revenue** | $363856 | $67612 | $296244 | 438.2% |

---

Technology services revenue increased by $296,244 for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The increase is due to increases in the number of lives tracked.

***Cost of Revenues (Excluding Depreciation and Amortization) and Gross Profit***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Cost of revenue (including stock-based compensation) | $6307385 | $7108407 | $(801022) | (11.3)% |

---

Cost of revenues (including stock-based compensation) decreased by $801,022, or 11.3%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The decrease in cost of revenues is primarily due to a decrease of $1,054,331 in origination commissions due to a decrease in amount of policies originated to subsidiaries eliminated in consolidation (refer to the *Key Business Metrics* section below for the the comparison of the number of policy originations to subsidiaries eliminated in consolidation), and $246,342 asset management retrocession fees mainly due to a decrease in the AUM of the ETF Funds (refer to the R*esults of Operations—Segment Results—Asset Management* section below) partially offset by an increase of $368,541 related to compensation expenses due to increase in employees in connection with the Company's 2025 business acquisitions.

***Operating Expenses***

*Sales and Marketing Expenses*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Sales and marketing | $4947910 | $2616000 | $2331910 | 89.1% |

---

Sales and marketing expenses increased by $2,331,910 or 89.1%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The increase was primarily related to an increase in advertising costs to support our life solutions growth strategy.

*General and Administrative (Including Stock-Based Compensation) Expenses*

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| General and administrative (including stock-based compensation) | $25872125 | $12263786 | $13608339 | 111.0% |

---

General and administrative (including stock-based compensation) increased by $13,608,339, or 111.0%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The increase is primarily related to increases in payroll expense of $4,507,070 mainly due to increase in staffing due to acquisitions, an increase in non-cash stock-based compensation expense of $3,801,656, and increase in legal and professional fees of $3,095,461 incurred in connection with various projects, and other general and administrative expenses of $1,590,159.

*Depreciation and Amortization Expense*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Depreciation and amortization expense | $3934086 | $4758546 | $(824460) | (17.3)% |

---

The decrease of $824,460, or 17.3%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 in depreciation and amortization expense is primarily related to certain intangible assets reaching the end of their estimated useful lives.

*Unrealized Loss (Gain) on Equity Securities, at Fair Value*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Gain on equity securities, at fair value | $— | $(272254) | $272254 | (100.0)% |

---

Unrealized gain on investments decreased by $272,254 or 100.0% for the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The Company no longer invests in S&P 500 options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(Gain) Loss on Change in Fair Value of Debt*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Gain on change in fair value of debt | $— | $(3362103) | $3362103 | (100.0)% |

---

Gain on change in fair value of debt decreased by $3,362,103 or 100.0% for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The Company paid off its market-indexed notes in 2025.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

***Other Income (Expense)***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Other income (expense), net | $2518593 | $(44524) | $2563117 | (5756.7)% |
| Interest expense | (10453592) | (9618330) | (835262) | 8.7% |
| Interest income | 663223 | 1175001 | (511778) | (43.6)% |
| Loss on change in fair value of warrant liability |  | (4806000) | 4806000 | (100.0)% |
| Total other income (expense) | $(7271776) | $(13293853) | $6022077 | (45.3)% |

---

Other income increased by $2,563,117 or 5,756.7%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The change is primarily related to an unrealized gain of $5,400,000 on one equity investment, partially offset by a $3,050,000 impairment on a separate equity investment. See Note 9, *Other Investments and Other Assets.*

Interest expense increased by $835,262 or 8.7% for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The increase in interest expense is primarily related to the $50,000,000 delayed draw borrowed in September 2025 that was available under the Senior Secured Credit Facility.

Interest income decreased by $511,778 or 43.6% for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The decrease in interest income is related to interest earned on our bank deposits.

The loss on change in fair value of warrant liability decreased by $4,806,000 or 100.0% for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The change is primarily attributable to the redemption of all the Private Placement Warrants offset by the issuance of common stock in 2025.

***Income Tax Expense***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Income tax expense | $3790814 | $2334085 | $1456729 | 62.4% |

---

Income tax expense increased by $1,456,729, or 62.4% for the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The change was primarily driven by the increase in net income and the impact of permanent differences due to compensation related expenses. Our effective income tax rate for the three months ended March 31, 2026 and for the three months ended March 31, 2025, was 34.3% and 30.2%, respectively.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**Results of Operations—Segment Results**

***Asset Management***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Revenue | $8459144 | $7773077 | $686067 | 8.8% |
| Cost of revenue | 2595978 | 2742018 | (146040) | (5.3)% |
| Gross profit | $5863166 | $5031059 | $832107 | 16.5% |

---

The change in revenue is explained above under Revenue. The composition of cost of revenue is described in Note 2, *Summary of Significant Accounting Policies* in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Cost of revenue from our asset management segment decreased by $146,040, or 5.3%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025, primarily due to a decrease in the ETF Funds' AUM.

The change in gross profit is a product of the change of revenue and cost of revenue.

***Assets Under Management***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | **Longevity Funds** | **ETF Funds** | **Total** |
| **BALANCE AS OF DECEMBER 31, 2025 - Fee Paying AUM** | $2236660654 | $850607003 | $3087267657 |
| &nbsp;&nbsp;Inflows | 288057565 | 89995913 | 378053478 |
| &nbsp;&nbsp;Outflows | (14365040) | (391285328) | (405650368) |
| &nbsp;&nbsp;Change in value | (73024300) | 178256570 | 105232270 |
| &nbsp;&nbsp;Value of all policies on the balance sheet related to LMA Income Series II, LP<sup>[1]</sup> | 106926040 |  | 106926040 |
| **BALANCE AS OF MARCH 31, 2026 - Fee Paying AUM** | 2544254919 | 727574158 | 3271829077 |
| OTHER POLICY BALANCE SHEET ASSETS - Non-Fee Paying | 286776176 |  | 286776176 |
| **TOTAL ASSETS UNDER MANAGEMENT AS OF MARCH 31, 2026** | $2831031095 | $727574158 | $3558605253 |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **Longevity Funds** | **ETF Funds** | **Total** |
| **BALANCE AS OF DECEMBER 31, 2024 - Fee Paying AUM** | $1815438972 | $778641321 | $2594080293 |
| &nbsp;&nbsp;Inflows | 128194329 | 88965396 | 217159725 |
| &nbsp;&nbsp;Outflows | (9122929) | (84333558) | (93456487) |
| &nbsp;&nbsp;Change in value | (23455597) | (24695885) | (48151482) |
| &nbsp;&nbsp;Value of all policies on the balance sheet related to LMA Income Series, LP<sup>[1]</sup> | 7093776 |  | 7093776 |
| &nbsp;&nbsp;Value of all policies on the balance sheet related to LMA Income Series II, LP<sup>[1]</sup> | 141399981 |  | 141399981 |
| **BALANCE AS OF MARCH 31, 2025 - Fee Paying AUM** | 2059548532 | 758577274 | 2818125806 |
| OTHER POLICY BALANCE SHEET ASSETS - Non-Fee Paying | 298811072 |  | 298811072 |
| **TOTAL ASSETS UNDER MANAGEMENT AS OF MARCH 31, 2025** | $2358359604 | $758577274 | $3116936878 |

---

<sup>[1]</sup> Recurring revenues generated are eliminated in consolidation.

**Longevity Funds**—The change in inflows are related to new subscriptions of approximately $288.1 million. The outflows are related to redemptions of approximately $14.4 million. The change in value of approximately $73.0 million is the result of realized and unrealized gains generated by investments in life settlement policies, net of operating expenses.

**ETF Funds**—The change in inflows are related to new subscriptions of approximately $90.0 million. The outflows are related to redemptions of approximately $391.3 million. The change in value of approximately $178.3 million is the result of realized and unrealized gains generated by underlying investments, net of operating expenses.

***Life Solutions***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Revenue | $50567288 | $36298657 | $14268631 | 39.3% |
| Cost of revenue | 3085681 | 3900859 | (815178) | (20.9)% |
| Gross profit | $47481607 | $32397798 | $15083809 | 46.6% |

---

The change in revenue is explained above under Revenue. The composition of cost of revenue is described in Note 2, *Summary of Significant Accounting Policies* in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Cost of revenue from our life solutions segment decreased by $815,178, or 20.9%, for the three months ended March 31, 2026, compared to the three months ended March 31, 2025, mainly due to a decrease in compensation related expenses.

The change in gross profit is a product of the change of revenue and cost of revenue.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

***Technology Services***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Revenue | $363856 | $67612 | $296244 | 438.2% |
| Cost of revenue | 625726 | 465530 | 160196 | 34.4% |
| Gross loss | $(261870) | $(397918) | $136048 | (34.2)% |

---

The change in revenue is explained above under Revenue. The composition of cost of revenue is described in Note 2, *Summary of Significant Accounting Policies* in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Cost of revenue from our technology services segment increased by $160,196, or 34.4%, for the three months ended March 31, 2026, compared to the three months ended March 31, 2025, mainly due to an increase in compensation related expenses.

The change in gross loss is a product of the change of revenue and cost of revenue.

**Non-GAAP Financial Measures and Key Business Metrics**

The consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP. We monitor key business metrics and non-GAAP financial measures that assist us in evaluating our business, measuring our performance, identifying trends and making strategic decisions. We have presented the following non-GAAP measures, their most directly comparable GAAP measure, and key business metrics:

---

| | |
|:---|:---|
| **<u>Non-GAAP Measure</u>** | **<u>Comparable GAAP Measure</u>** |
| Adjusted Net Income, Adjusted EPS | Net Income attributable to common stockholders and EPS |
| Adjusted EBITDA | Net Income |

---

Adjusted Net Income, Adjusted EPS, Adjusted EBITDA and Adjusted EBITDA Margin, are not measures of financial performance under GAAP and should not be considered substitutes for GAAP measures, net income (loss) (for Adjusted EBITDA and Adjusted EBITDA Margin), net income (loss) attributable to common stockholders (for Adjusted Net Income) or earnings (loss) per share (for Adjusted EPS), which are considered to be the most directly comparable GAAP measures. These non-GAAP financial measures have limitations as analytical tools, and when assessing Company's operating performance, these non-GAAP financial measures should not be considered in isolation or as substitutes for net income (loss), net income (loss) attributable to common stockholders, earnings (loss) per share or other consolidated statements of operations and comprehensive income (loss) data prepared in accordance with GAAP.

Adjusted Net Income is presented for the purpose of calculating Adjusted EPS. The Company defines Adjusted Net Income as net income (loss) attributable to common stockholders adjusted for non-controlling interest income, amortization, change in fair value of warrants, business acquisition costs and special legal costs, and non-cash stock-based compensation and the related stock-based limitation tax effect before the estimated tax effect. The estimated tax effect to adjusted net income is based on the Company's U.S. based federal and state statutory tax rates. We believe that Adjusted Net Income provides an additional measure of operating performance that eliminates the impact of expenses that do not relate to business performance.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

Adjusted EPS measures our per share earnings and is calculated as Adjusted Net Income divided by adjusted weighted-average shares outstanding. We believe that Adjusted EPS may be useful to investors because it enables them to better evaluate per share operating performance across reporting periods by eliminating the impact of expenses that do not relate to the Company's business performance.

**Adjusted Net Income and Adjusted EPS**

The following table presents a reconciliation of Adjusted Net Income to the most comparable GAAP financial measure, net income attributable to common stockholders and Adjusted EPS to the most comparable GAAP financial measure, earnings per share, on a historical basis for the periods indicated below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **Gross** | **Estimated Tax** <sup>[2]</sup> | **Net** | **Gross** | **Estimated Tax** <sup>[2]</sup> | **Net** |
| **NET INCOME ATTRIBUTABLE TO ABACUS GLOBAL MANAGEMENT, INC.** | $7266192 | $— | $7266192 | $4639583 | $— | $4639583 |
| &nbsp;&nbsp;Net income attributable to noncontrolling interests |  |  |  | 759443 |  | 759443 |
| &nbsp;&nbsp;Amortization expense | 3824053 | (969206) | 2854847 | 4691720 | (1189117) | 3502603 |
| &nbsp;&nbsp;Stock-based compensation | 6343401 | (1607735) | 4735666 | 2355395 | (596975) | 1758420 |
| &nbsp;&nbsp;Unrealized gain on investments | (5400000) | 1368630 | (4031370) |  |  |  |
| &nbsp;&nbsp;Impairment on investments | 3050000 | (773023) | 2276977 |  |  |  |
| &nbsp;&nbsp;Business acquisition and special projects costs | 3949340 | (1000960) | 2948380 |  |  |  |
| &nbsp;&nbsp;Loss on change in fair value of warrant liability |  |  |  | 4806000 | (1218081) | 3587919 |
| &nbsp;&nbsp;Other | 103561 |  | 103561 |  |  |  |
| &nbsp;&nbsp;Tax impact <sup>[1]</sup> | 971199 |  | 971199 |  |  |  |
| **ADJUSTED NET INCOME** | $20107746 | $(2982294) | $17125452 | $17252141 | $(3004172) | $14247969 |
| **WEIGHTED-AVERAGE STOCK OUTSTANDING—BASIC** | 96775889 | 96775889 | 96775889 | 96193199 | 96193199 | 96193199 |
| **WEIGHTED-AVERAGE STOCK OUTSTANDING—DILUTED** | 99545644 | 99545644 | 99545644 | 97498923 | 97498923 | 97498923 |
| **ADJUSTED EPS - BASIC** | $0.21 | $(0.03) | $0.18 | $0.18 | $(0.03) | $0.15 |
| **ADJUSTED EPS - DILUTED** | $0.20 | $(0.03) | $0.17 | $0.18 | $(0.03) | $0.15 |

---

[1] Tax impact mainly represents the permanent difference in tax expense related to the restricted stock awards granted to certain executives due to IRC 162(m) limitations.

<sup>[2]</sup> The estimated tax is based on the net federal and state statutory rate.

Note: Totals may not add up due to rounding.

The change in adjusted net Income was primarily a result of the factors described in connection with operating revenues and operating expenses and the items listed above.

**Adjusted EBITDA and Adjusted EBITDA Margin**

Adjusted EBITDA is net income adjusted for depreciation expense, amortization, interest expense, income tax, business acquisition costs and special legal costs, non-cash expenses, and certain other items that in our judgment significantly impact the period-over-period assessment of performance and operating results that do not directly relate to business performance within the Company's control. These items

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

may include payments made as part of the Company's expense support commitment, change in fair value of debt, change in fair value of warrant liability, S&P 500 options that were entered into as an economic hedge related to the debt (described as the realized and unrealized gain on equity securities, at fair value), non-cash stock based compensation, and other items. Adjusted EBITDA should not be determined as substitution for net income (loss), cash flows from operating, investing, and financing activities, operating income (loss), or other metrics prepared in accordance with U.S. GAAP.

We believe that Adjusted EBITDA assists investors in understanding the Company's ongoing operating performance by presenting comparable financial results between periods. We believe that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes, and certain other charges that are variable from year to year. We believe that Adjusted EBITDA provides our investors with performance measures that reflect the impact to operations from trends in changes in revenue, policy values, and operating expenses that provides a perspective not immediately apparent from net income (loss) and operating income (loss). Adjusted EBITDA excludes items which we believe may cause short-term fluctuations in net income (loss) and operating income (loss) which we do not consider to be the primary drivers of the Company's business.

The following table presents a reconciliation of Adjusted EBITDA and Adjusted EBITDA margin to the most comparable GAAP financial measure, net income, on a historical basis:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **NET INCOME** | 7266192 | 5399026 |
| &nbsp;&nbsp;Depreciation and amortization expense | 3934086 | 4758546 |
| &nbsp;&nbsp;Income tax expense | 3790814 | 2334085 |
| &nbsp;&nbsp;Interest expense | 10453592 | 9618330 |
| &nbsp;&nbsp;Other income (expense), net | (168593) | 44524 |
| &nbsp;&nbsp;Interest income | (663223) | (1175001) |
| &nbsp;&nbsp;Loss on change in fair value of warrant liability |  | 4806000 |
| &nbsp;&nbsp;Stock-based compensation | 6343401 | 2355395 |
| &nbsp;&nbsp;Unrealized gain on investments | (5400000) |  |
| &nbsp;&nbsp;Impairment on investments | 3050000 |  |
| &nbsp;&nbsp;Business acquisition and special projects costs | 3949340 |  |
| &nbsp;&nbsp;Other | 103561 |  |
| &nbsp;&nbsp;Unrealized gain on equity securities, at fair value |  | (272254) |
| &nbsp;&nbsp;Loss (gain) on change in fair value of debt |  | (3362103) |
| **Adjusted EBITDA** | 32659170 | 24506548 |
| **TOTAL REVENUE** | 59390288 | 44139346 |
| **Adjusted EBITDA Margin** | 55.0% | 55.5% |
| **Net Income Margin** | 12.2% | 12.2% |

---

The change in adjusted EBITDA was primarily a result of the factors described in connection with operating revenues and operating expenses and the items listed above.

**Key Business Metrics**

We monitor the following key business metrics:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue generated from life policies: (i) policies sold, matured, and bought, (ii) realized gains, (iii) revenues from maturities, (iv) net death benefit value of policies held, (v) turnover ratio, and (vi)

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

holding period. The number of policies sold and purchased helps us measure the level of trading activity for the period that leads to realized and unrealized gains, respectively. Realized gains on sold policies and revenues from maturities is used to measure our profit optimization. The net death benefit of policies represents the maximum potential maturity revenue realization on policies held. The turnover ratio measures our capital efficiency with a higher number generally correlating to growth in realized gains. The holding period is based on the weighted average age of life settlement policies, which tracks our ability to make hold or trade decisions that enhance realized gains.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Asset management revenue: (i) assets under management also referred to as the net asset value of funds ("AUM" or "NAV"). AUM drives management fees and performance fees generated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Servicing revenue: (i) number of policies serviced, (ii) face value of policies serviced, and (iii) total invested dollars. Servicing revenue involves the provision of services for maintaining the policy, managing processing of claims in the event of death of the insured, and ensuring timely payment of optimized premiums computed to derive maximum return on maturity of the policy. The number of policies and the face value of policies serviced represents the volume and dollar face value of policies over which the above services are performed. Total invested dollars represent the acquisition cost plus premiums paid for serviced policies and is used to determine servicing fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Origination revenue: Origination revenues represent fees negotiated for each purchase and sale of a policy with an investor. The number of policy originations (i) represents the volume of policies over which the above origination services are performed. The number of policy originations directly correlates with origination revenues allowing management to evaluate fees earned upon each transaction.

Information regarding policies accounted for under the fair value method is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Fair Value Method: |  |  |  |  |
| &nbsp;&nbsp;Policies bought | 203 | 171 | 32 | 18.7% |
| &nbsp;&nbsp;Policies bought from related parties | 2 |  | 2 | NM |
| &nbsp;&nbsp;Policies originated for external investors <sup>[1]</sup> | 35 | 31 | 4 | 12.9% |
| &nbsp;&nbsp;Policies sold | 331 | 118 | 213 | 180.5% |
| &nbsp;&nbsp;Policies sold to related parties | 305 | 40 | 265 | 662.5% |
| &nbsp;&nbsp;Policies matured | 16 | 15 | 1 | 6.7% |
| &nbsp;&nbsp;Turnover ratio <sup>[2]</sup> | 1.9 | <sup>[2]</sup> | NM | NM |
| &nbsp;&nbsp;Holding period on existing policies (in days) | 209 | <sup>[2]</sup> | NM | NM |
| &nbsp;&nbsp;Holding period on sold policies (in days) | 290 | <sup>[2]</sup> | NM | NM |
| &nbsp;&nbsp;Weighted average realized gain on policies sold [3] | 26.4% | 21.0% | 5.4% | 25.7% |
| &nbsp;&nbsp;Number of external counter parties that purchased policies | 8 | 19 | (11) | (57.9)% |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| &nbsp;&nbsp;Total lifetime realized gains, net of lifetime premiums paid | $60769398 | $13875116 | $46894282 | 338.0% |
| &nbsp;&nbsp;Total lifetime realized gains from maturities, net of lifetime premiums paid | $3308687 | $6907327 | $(3598640) | (52.1)% |

---

<sup>[1]</sup> - 2026 includes 8 policies and 2025 includes 6 policies within the rescission period that are recorded in contract liabilities on the Company's consolidated balances sheets. Refer to Note 4, *Revenue* for additional information.

<sup>[2]</sup> - The Company will report the turnover ratio and holding periods on a prospective basis.

<sup>[3]</sup> - The weighted average realized gain percentage on policies sold is not annualized and can vary materially from an annualized return depending on the holding period. Two transactions with the same realized gain percentage may reflect materially different annualized returns due to differences in time held.

Note: Realized gains represent the difference between the sale price of life insurance policies or the net death benefit of matured life insurance policies, net of the original cost of the corresponding life settlement policy plus related lifetime continuing costs (e.g., premium costs) (together all costs associated with life insurance policies are "Lifetime Carrying Costs"). The average realized gain on policies sold represents realized gains as a percentage of related Lifetime Carrying Costs of sold life insurance policies. Sales to related parties resulted in average realized gains of 26.4% (ranging from 22% to 41%) compared to average realized gains of 10% from sales to external parties ranging from (3% to 40%) during the three months ended March 31, 2026. There were no significant differences in the weighted average realized gains from life settlement policies sold to external- versus related-parties for the three months ended March 31, 2025. Refer to Note 19, *Related-Party Transactions* for additional information.

The increase in total lifetime realized gains is mainly due to the increase in total policies sold compared to the same period in 2025.

Information regarding originations revenue, management fees, and servicing revenue is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Assets under management (external fee paying) | $3164903037 | $2542185454 | $622717583 | 24.5% |
| Average management fee on Longevity Funds | 1.14% | 1.49% | (0.35)% | (23.5)% |
| Average management fee on ETF Funds | 0.50% | 0.38% | 0.12% | 31.6% |
| Number of policies serviced <sup>[1]</sup> | 3664 | 2415 | 1249 | 51.7% |
| Face value of policies serviced <sup>[1]</sup> | $7817055669 | $6119634672 | $1697420997 | 27.7% |
| Total invested dollars <sup>[1]</sup> | $3279832767 | $2556019697 | $723813070 | 28.3% |
| Number of policies serviced, related party | 2566 | 1354 | 1212 | 89.5% |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| | **2026** | **2025** |<br>**Change** |<br>**% Change** |
| Face value of policies serviced, related party | $5772524696 | $3579806381 | $2192718315 | 61.3% |
| Total invested dollars, related party | $2483428548 | $1733851114 | $749577434 | 43.2% |
| Number of policy originations to external parties | 35 | 31 | 4 | 12.9% |
| Number of policy originations to subsidiaries eliminated in consolidation <sup>[2]</sup> | 126 | 151 | (25) | (16.6)% |

---

<sup>[1]</sup> For the three months ended March 31, 2026, LMA and LMA subsidiaries comprised 704 of the policies serviced, $837,144,010 face value of the policies serviced, and $355,200,597 of the total invested dollars. For the three months ended March 31, 2025, LMA and LMA subsidiaries comprised 736 of the policies serviced, $1,379,845,928 face value of the policies serviced, and $334,557,381 of the total invested dollars. All servicing revenues related to LMA or LMA subsidiaries are eliminated in consolidation. Total invested dollars represent the acquisition cost plus premiums paid for serviced policies and is used to determine servicing fees.

<sup>[2]</sup> Number of policy originations to subsidiaries eliminated in consolidation shows the level of policies acquired by the Company in the secondary market. Refer to Note 13, *Fair Value Measurements* for definition of the secondary market.

Refer to the R*esults of Operations—Segment Results—Asset Management* section above for the change related to change in assets under management (external fee paying).

**Liquidity and Capital Resources**

The Company finances its operations primarily through cash generated from operations and net proceeds from debt or equity financing. The Company actively manages its working capital and the associated cash requirements when servicing and originating policies while also effectively utilizing cash and other sources of liquidity to purchase additional life settlement policies. As of March 31, 2026 and December 31, 2025, our principal source of liquidity was cash and cash equivalents totaling $37,209,747 and $38,112,332, respectively.

Our future capital requirements will depend on many factors, including our revenue growth rate. The Company. may, in the future, enter into arrangements to acquire or invest in complementary businesses, products, and technologies. The Company may seek additional equity or debt financing.

Refer to Note 15, *Convertible Preferred Stock and Stockholders' Equity* for information on our share repurchase plans.

We believe that our current cash and cash equivalents as well as cash generated from operations will be sufficient to support our operating and debt service needs for the 12 months following the filing of this Yearly Report on Form 10-K.

***Cash Flows from our Operations***

The following table summarizes our cash flows for the periods presented:

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**Change** |
| Net cash provided by (used in) operating activities | $91686413 | $(61590694) | $153277107 |
| Net cash used in investing activities | (931742) | (3739403) | 2807661 |
| Net cash used in financing activities | (91657256) | (22852454) | (68804802) |
| &nbsp;&nbsp;&nbsp;Net change in cash and cash equivalents | $(902585) | $(88182551) | $87279966 |

---

*Operating Activities*

During the three months ended March 31, 2026, our operating activities provided $91,686,413 of net cash compared to $61,590,694 of net cash used from operating activities during the three months ended March 31, 2025. The increase of $153,277,107 in net cash provided from operating activities was primarily due to $89,678,620 increase in net life policy settlement sales and $62,217,803 decrease in the fair value of held life policy settlements.

*Investing Activities*

During the three months ended March 31, 2026, investing activities used $931,742 of net cash compared to $3,739,403 net cash used during the three months ended March 31, 2025. The decrease of $2,807,661 in net cash used in investing activities was primarily related to $3,450,000 purchases of investments that did not recur.

*Financing Activities*

During the three months ended March 31, 2026, financing activities used $91,657,256 of net cash compared to $22,852,454 of net cash used during the three months ended March 31, 2025. The increase of $68,804,802 in net cash used by financing activities is primarily due to $39,437,739 increase in debt repayments, and $14,453,988 increase in share repurchases,offset by $15,445,504 decrease in issued debt.

***Contractual Obligations and Commitments***

Refer to the following notes in our Interim Financial Statements for a list of contractual obligations and commitments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 12, *Commitments and Contingencies* for a list of commitments and contingencies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 14, *Long-Term Debt* for a list of outstanding debt, related interest rates, and maturity dates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 20, *Leases* for our outstanding lease obligations.

**Critical Accounting Policies and Estimates**

The Company prepared its consolidated financial statements in accordance with GAAP. Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements, as well as revenue and expense recorded during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and or other relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ materially from management's estimates. Refer to Note 2, *Summary of Significant Accounting Policies*, within the 2025 Annual Report.

**Recent Accounting Pronouncements**

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

See Note 2, *Summary of Significant Accounting Policies,* to the Interim Financial Statements and within the 2025 Annual Report for a discussion of recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.

\*\*\*\*\*

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

**Item 4. Controls and Procedures**

***Evaluation of Disclosure Controls and Procedures***

As required by Rule 13a-15(e) or Rule 15d-15(e) promulgated by the SEC under the Securities Exchange Act of 1934, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q at the reasonable assurance level.

***Changes in Internal Control Over Financial Reporting***

There has been no change in our internal control over financial reporting during the three months ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Part II**

**Item 1. Legal Proceedings**

From time to time, the Company is involved in various civil actions as part of its normal course of business. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of these matters will be. However, the Company believes, based on current knowledge and after consultation with counsel, that the Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the end of the period to which this Report relates.

**Item 1A. Risk Factors**

Factors that could cause our actual results to differ materially from those in this report include the risk factors described in our 2025 Annual Report on Form 10-K filed with the SEC on March 13, 2026. As of the date of this Report, there have been no material changes to the risk factors disclosed in our 2025 Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

*Purchases of equity securities by the issuer*

Refer to Note 15, *Convertible Preferred Stock and Stockholders' Equity* to the consolidated financial statements for further discussion of our stock repurchase program.

**Item 3. Defaults Upon Senior Securities**

None.

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

During the quarter ended March 31, 2026, none of the Company's officers or directors (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated any "Rule 10b5-1 trading arrangement" or any "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408 of Regulation S-K.

**Item 6. Exhibits**

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 2.1 | [Agreement and Plan of Merger, dated as of August 30, 2022, by and among East Resources Acquisition Company, LMA Merger Sub, LLC, Abacus Merger Sub, LLC, Longevity Market Assets, LLC and Abacus Settlements, LLC, incorporated by reference to Exhibit 2.1 from the Company's Form 8-K filed on August 30, 2022.](https://www.sec.gov/Archives/edgar/data/1814287/000156459022030357/eresu-ex21_7.htm) |
| 2.2 | [First Amendment to Agreement and Plan of Merger, dated as of October 14, 2022, by and among East Resources Acquisition Company, LMA Merger Sub, LLC, Abacus Merger Sub, LLC, Longevity Market Assets, LLC and Abacus Settlements, LLC, incorporated by reference to Exhibit 2.1 from the Company's Form 8-K filed on October 14, 2022.](https://www.sec.gov/Archives/edgar/data/1814287/000119312522262995/d326265dex21.htm) |
| 2.3 | [Second Amendment to Agreement and Plan of Merger, dated as of April 20, 2023, by and among East Resources Acquisition Company, LMA Merger Sub, LLC, Abacus Merger Sub, LLC, Longevity Market Assets, LLC and Abacus Settlements, LLC (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K (File No. 001-39403) filed with the SEC on April 20, 2023), incorporated by reference to Exhibit 2.1 from the Company's Form 8-K filed on April 20, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523108364/d479667dex21.htm) |
| 2.4 | [Share Purchase Agreement, by and among Abacus Life, Inc., Carlisle Management Company S.C.A., Carlisle Investment Group S.A.R.L., the Sellers party thereto, Jose Eseteban Casares Garcia, Manorhaven Holdings, LLC, Pacific Current Group Limited, certain equityholders of CMC Vehicle, LLC and Pillo Portsmouth Holding Company, LLC, in its capacity as the Sellers' Representative thereunder, dated as of July 18, 2024, incorporated by reference to Exhibit 2.1 from the Company's Form 8-K filed on July 18, 2024](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000045/projectleo-sharepurchase.htm). |
| 3.1 | [Second Amended and Restated Certificate of Incorporation of Abacus Life, Inc., incorporated by reference from to Exhibit 3.1 of the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex31.htm) |
| 3.2 | [Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Abacus Life, Inc., dated February 27, 2025, incorporated by reference to Exhibit 3.1 from the Company's Form 8-K filed on March, 5, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000181428725000003/exhibit31-amendedcertifi.htm) |
| 3.3 | [Amended and Restated Bylaws of the Company, dated February 27, 2025, incorporated by reference to Exhibit 3.3 of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 8, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000181428725000006/exhibit33_bylawsofabl02272.htm) |
| 4.1 | Specimen Common Share Certificate[, incorporated by reference to Exhibit 4.1 from the Company's Form 8-A/A filed on December 29, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000162828025058825/ex41specimencommonstockcer.htm) |
| 4.2 | [Unsecured Promissory Note, dated as of June 30, 2023, issued to Sponsor, incorporated by reference to Exhibit 4.4 from the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex44.htm) |
| 4.3 | [Amended and Restated Unsecured Promissory Note, dated as of July 5, 2023, issued to East Asset Management, LLC, incorporated by reference to Exhibit 4.5 from the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex45.htm) |
| 4.4 | [Base Indenture, dated November 10, 2023, between the Company and U.S. Bank Trust Company, National Association, as Trustee, incorporated by reference to Exhibit 4.1 from the Company's Form 8-K filed on November 13, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523276009/d319936dex41.htm) |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 4.5 | First S[upplemental Indenture, dated November 10, 2023, between the Company and U.S. Bank Trust Company, National Association, as Trustee, including the form of 9.875% Fixed Rate Senior Note due 2028 existing notes, incorporated by reference to Exhibit 4.2 from the Company's Form 8-K filed on November 13, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523276009/d319936dex42.htm) |
| 4.6 | [Form of 9.875% Fixed Rate Senior Notes due 2028, incorporated by reference to Exhibit A of Exhibit 4.2 from the Company's Form 8-K filed on November 13, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523276009/d319936dex42.htm) |
| 4.7 | [Second Supplemental Indenture, dated as of December 2, 2024, between the Company and U.S. Bank Trust Company, National Association, as Trustee, including the form of the notes, incorporated by reference to Exhibit 4.3 from the Company's Form 8-K filed on December 2, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000068/exhibit43_carlislesecondsu.htm) |
| 4.8 | [Third Supplemental Indenture, dated as of July 18, 2025, between the Company and U.S. Bank Trust Company, National Association, as Trustee, incorporated by reference to Exhibit 4.7 of the Company's Form S-3 filed November 25, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000114036125043363/ny20059688x1_ex4-7.htm) |
| 4.9 | [Description of registrant's securities.](https://www.sec.gov/Archives/edgar/data/1814287/000162828026017775/exhibit49_abxdescriptionof.htm) |
| 4.10 | Certificate of Designations of Abacus Global Management, Inc., designating the Company's Series A Convertible Preferred Stock, par value $0.0001 per share, [incorporated by reference to Exhibit 3.1 from the Company's Form 8-K filed on March 24, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000181428725000004/a31excertificateofdesignat.htm) |
| 10.1 | [Form of Indemnification Agreement, incorporated by reference to Exhibit 10.6 from the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex106.htm) |
| 10.2 | [Abacus Life, Inc. Amended and Restated 2024 Long-Term Equity Compensation Incentive Plan, incorporated by reference from Appendix A to the Company's Proxy Statement filed on April 29, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000030/abacuslifedef14a.htm) |
| 10.3 | [Form of Restricted Stock Unit Award granted under the Abacus Life, Inc. Amended and Restated 2024 Long-Term Equity Compensation Incentive Plan, incorporated by reference to Exhibit 10.1 from the Company's Form 8-K filed on December 16, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000074/exhibit101-formofabacusrsu.htm) |
| 10.4 | [Abacus Life, Inc. 2023 Long-Term Equity Incentive Plan, incorporated by reference to Exhibit 10.7 from the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex107.htm) |
| 10.5 | [Form of Restricted Stock Unit Award granted under the Abacus Life, Inc. 2023 Long-Term Equity Incentive Plan, incorporated by reference to Exhibit 10.8 from the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex108.htm) |
| 10.6 | [Form of Option Award granted under the Abacus Life, Inc. 2023 Long-Term Equity Incentive Plan, incorporated by reference to Exhibit 10.9 from the Company's Form 8-K filed on July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex109.htm) |
| 10.7 | [Credit Agreement, dated as of December 10, 2024, by and among Abacus Life, Inc. as the Borrower, GLAS USA LLC, as the Administrative Agent, GLAS AMERICAS LLC, as the Collateral Agent and the Lenders from time to time party thereto, incorporated by reference to Exhibit 10.1 from the Company's Form 8-K filed on December 10, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000162828024050657/exhibit101creditagreement.htm) |
| 10.8 | [Security Agreement, dated as of December 10, 2024, by and among the Grantors party thereto and GLAS USA LLC as Collateral Agent, incorporated by reference to Exhibit 10.2 from the Company's Form 8-K filed on December 10, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000162828024050657/exhibit102securityagreement.htm) |
| 10.9 | [Guaranty, dated as of December 10, 2024 among Abacus Life, Inc. the Guarantors party thereto, and GLAS USA LLC as Administrative Agent, incorporated by reference to Exhibit 10.3 from the Company's Form 8-K filed on December 10, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000162828024050657/exhibit103guaranty.htm) |
| 10.10 | [Form of Employment Agreement, incorporated by reference to Exhibit 10.10 from the Company's Form S-1 filed on July 25, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523193281/d527481dex1010.htm) |
| 10.11 | [Sponsor Support Agreement, dated as of August 30, 2022, by and among the East Resources Acquisition Company, Sponsor, LMA and Legacy Abacus, incorporated by reference from the Company's Form 8-K filed August 30, 2022.](https://www.sec.gov/Archives/edgar/data/1814287/000156459022030357/eresu-ex101_9.htm) |
| 10.12 | [Amendment No. 1 to the Sponsor Support Agreement, dated as of December 20, 2023, by and among Abacus Life, Inc., Longevity Market Assets, LLC, Abacus Settlements, LLC and East Sponsor, LLC, incorporated by reference from the Company's 8-K filed December 29, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000181428723000054/a101-amendment_1xtoxspon.htm) |
| 10.13 | [Company Support Agreement, dated as of August 30, 2022, by and among East Resources Acquisition Company, LMA, Legacy Abacus and the other parties signatory thereto, incorporated by reference from the Company's Form 8-K filed August 30, 2022.](https://www.sec.gov/Archives/edgar/data/1814287/000156459022030357/eresu-ex102_8.htm) |

---

------

<u>[**Table of Contents**](#i8f8164e49047434386656455d13714da_753)</u>

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 10.14 | [Amendment No. 1 to the Company Support Agreement, dated as of December 20, 2023, by and among Abacus Life, Inc., Longevity Market Assets, LLC, Abacus Settlements, LLC, T. Sean McNealy, K. Scott Kirby, Matthew A, Ganovsky incorporated by reference from the Company's 8-K filed December 29, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000181428723000054/a102-amendment_1xtoxcomp.htm) |
| 10.15 | [Share Lock-Up and Standstill Agreement, dated as of December 2, 2024, by and among the Company and the Stockholders party thereto, incorporated by reference from the Company's Form 8-K filed December 2, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000068/exhibit101_carlislesharelo.htm) |
| 10.16 | [Notes Registration Rights Agreement, dated as of December 2, 2024, by and among the Company and the Holders of the New Notes named therein, incorporated by reference from the Company's Form 8-K filed December 2, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000068/exhivit102_carlislenotesre.htm) |
| 10.17 | [Equity Registration Rights Agreement, dated as of December 2, 2024, by and among the Company and the Holders of the common stock of the Company named therein, incorporated by reference from the Company's Form 8-K filed December 2, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000068/exhivit103_carlisleequityr.htm) |
| 10.18 | [Form of Abacus Option Agreement 2024 Plan, incorporated by reference to Exhibit 10.21 of the Company's Annual Report for the year ended December 31, 2024 on Form 10-K, filed on March 28, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000181428725000006/exhibit1021_formofabacusop.htm) |
| 10.19 | [Form of Abacus RSU Agreement 2024 Plan, incorporated by reference to Exhibit 10.22 of the Company's Annual Report for the year ended December 31, 2024 on Form 10-K, filed on March 28, 2025.](https://www.sec.gov/Archives/edgar/data/1814287/000181428725000006/exhibit1022_formofabacusrs.htm) |
| 14.1 | [Code of Business Conduct and Ethics of Abacus Life, Inc., incorporated by reference from the Company's Form 8-K filed July 6, 2023.](https://www.sec.gov/Archives/edgar/data/1814287/000119312523182812/d525613dex141.htm) |
| 19.1 | [Insider Trading Policy](https://www.sec.gov/Archives/edgar/data/1814287/000181428725000006/exhibit191_ablinsidertradi.htm), incorporated by reference to Exhibit 97.1 of the Company's Annual Report for the year ended December 31, 2023 on Form 10-K, filed on March 21, 2024. |
| 21.1 | [Subsidiaries of the Company](https://www.sec.gov/Archives/edgar/data/1814287/000162828026017775/exhibit211_ablsubsidiaries.htm). |
| 31.1\* | [Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit311_certabxfs3312026.htm) |
| 31.2\* | [Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit312_certabxfs3312026.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit321_certabxfs3312026.htm) |
| 32.2\*\* | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit322_certabxfs3312026.htm) |
| 97.1 | [Clawback policy, incorporated by reference to Exhibit 97.1 of the Company's Annual Report for the year ended December 31, 2023 on Form 10-K, filed on March 21, 2024.](https://www.sec.gov/Archives/edgar/data/1814287/000181428724000028/clawbackpolicy12312023.htm) |
| 101.INS\* | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document. |
| 101.CAL\* | XBRL Taxonomy Calculation Linkbase Document. |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB\* | XBRL Taxonomy Label Linkbase Document. |
| 101.PRE\* | XBRL Taxonomy Presentation Linkbase Document. |
| 104\* | [Cover Page Interactive Data File (embedded within the Inline XBRL document)](#i8f8164e49047434386656455d13714da_1) |
|  | \* Filed herewith |
|  | \*\* Furnished herewith |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| **ABACUS GLOBAL MANAGEMENT, INC.** | |
| By: | /s/ Jay Jackson |
|  | Jay Jackson |
|  | Chairman of the Board, |
|  | President and Chief Executive Officer |
|  | (Principal Executive Officer) |

---

Date: May 11, 2026

---

| | |
|:---|:---|
| By: | /s/ William McCauley |
|  | William McCauley |
|  | Chief Financial Officer and Chief Operating Officer |
|  | (Principal Financial Officer) |

---

Date: May 11, 2026

---

| | |
|:---|:---|
| By: | /s/ Alexei Solomon |
|  | Alexei Solomon |
|  | Chief Accounting Officer and Treasurer |
|  | (Principal Accounting Officer) |

---

Date: May 11, 2026

## Exhibit 31.1

<u>**Table of Contents**</u>

**EXHIBIT 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jay Jackson, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended March 31, 2026 of Abacus Global Management, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

------

<u>**Table of Contents**</u>

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 11, 2026

---

| |
|:---|
| /s/ Jay Jackson |
| Jay Jackson |
| Chairman of the Board, President and Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 31.2

<u>**Table of Contents**</u>

**EXHIBIT 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, William McCauley, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended March 31, 2026 of Abacus Global Management, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

------

<u>**Table of Contents**</u>

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 11, 2026

---

| |
|:---|
| /s/ William McCauley |
| William McCauley |
| Chief Financial Officer and Chief Operating Officer |
| (Principal Financial Officer) |

---

## Exhibit 32.1

<u>**Table of Contents**</u>

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350** 

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Abacus Global Management, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), I, Jay Jackson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Dated: May 11, 2026

---

| |
|:---|
| /s/ Jay Jackson |
| Jay Jackson |
| Chairman of the Board, <br>President and Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 32.2

<u>**Table of Contents**</u>

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350** 

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Abacus Global Management, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), I, William McCauley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Dated: May 11, 2026

---

| |
|:---|
| /s/ William McCauley |
| William McCauley |
| Chief Financial Officer and Chief Operating Officer |
| (Principal Financial Officer) |

---